

**Curriculum
Vitae**

**Prof.ssa Eugenia
Quiros Roldan**

Informazioni e recapiti personali

Cognome / Nome	Quiros Roldan M. Eugenia
Indirizzo	Via Costalunga n.8 - 25123, Brescia (BS), Italy.
Telefono	+39.030.3996618 (lavoro)
E-mail	eugeniaquiros@yahoo.it (privato) maria.quirosroldan@unibs.it (lavoro)
Nazionalità	Spagnola
Data di nascita	28/02/1964

Esperienze / Incarichi lavorativi

CARRIERA ACCADEMICA

Data	Dal 01/12/2016 Professore associato Malattie Infettive. Università degli Studi di Brescia
Data	Dal 31/10/2018 Abilitazione scientifica nazionale Settore Concorsuale 06/D4 - MED/17 MALATTIE INFETTIVE – I Fascia
Data Esperienza / Incarico	Dal 08/03/2005 ad oggi Professore Aggregato in Malattie Infettive Università degli Studi di Brescia
Data Esperienza / Incarico	Dal 08/03/2005 ad oggi Ricercatore in Malattie Infettive Università degli Studi di Brescia
Data Esperienza / Incarico	Dal 22/07/1996 a 01/01/2002 Personal de Investigaciòn e L.R.U.-2 de Facultad (Professore aggregato di Microbiologia) Universidad de Granada, Spagna
Data Esperienza / Incarico	Dal 10/1994 al 10/1997 Human Capital and Mobility Individual fellowship. European Union Community Combiotec. Italy
Data Esperienza / Incarico	Dall 1988 al 1994 Borsista Universidad de Granada, Spagna

INCARICHI DIDATTICI

A.A 2015/2016

U9277-Biotecnologie Mediche
U11794-Tecnico di laboratorio biomedico
Scuole di Specializzazione

A.A 2016/2017

U9277-Biotecnologie Mediche
Scuole di Specializzazione
Corsi opzionali o attività integrative

A.A 2017/2018

U11854-Assistenza Sanitaria
U9277-Biotecnologie Mediche
U11794-Tecnico di laboratorio biomedico
Scuole di Specializzazione
Corsi opzionali o attività integrative

A.A 2018/2019

U11854-Assistenza Sanitaria-Cremona
U9277-Biotecnologie Mediche
U11148-Infermieristica-Desenzano Del Garda
Scuole di Specializzazione

A.A 2019/2020

U11854-Assistenza Sanitaria-Cremona
U9277-Biotecnologie Mediche
U11148-Infermieristica-Desenzano Del Garda
U11148-Infermieristica-Cremona
Scuole di Specializzazione
Attività integrative

A.A 2020/2021

U11854-Assistenza Sanitaria-Cremona
U11794-Tecnico di Laboratorio Biomedico
U11148-Infermieristica-Desenzano Del Garda
U11148-Infermieristica-Cremona
Scuole di Specializzazione

CARRIERA ASSISTENZIALE-SANITARIA

Data	Dal 01/11/2020 ad oggi
Esperienza / Incarico	Dirigente Medico con incarico professionale di alta specializzazione, consulenza, studio e ricerca C1 Spedali Civili di Brescia

Data	Dal 01/07/2013 ad oggi
Esperienza / Incarico	Dirigente Medico con incarico professionale di alta specializzazione, consulenza, studio e ricerca C Spedali Civili di Brescia

Data	Dal 30/05/2003 a tutt'oggi
Esperienza / Incarico	Dirigente Medico Spedali Civili di Brescia

ISTRUZIONE E FORMAZIONE

Dal 1997 al 2001
Diploma di Specializzazione in Malattie Infettive
Università degli studi di Brescia, Italia

1990: PhD in Medicina e Chirurgia.
Università di Granada

1987: Laurea in Medicina e Chirurgia.
Università di Granada

MEMBRO DI GRUPPI DI RICERCA NAZIONALI:

- Membro della segreteria scientifica della coorte MASTER: Management standardizzato della terapia antiretrovirale
- Membro della segreteria scientifica della coorte ICONA: Italian Cohort of Antiretroviral Naïve Patients

PERIODI DI STUDIO E RICERCA IN ISTITUZIONI ESTERE:

- 1988 al 1991: Becas Plan Nacional de Investigación. Universidad de Granada, Spagna
- 1992-93: Beca Post-doctoral. University of Granada (Spain).
- 1994-97: Human Capital and Mobility Individual Fellowship from European Union Community
- 1996-2002: Researcher - Ayudante L.R.U-2. University of Granada. Spain

Articoli pubblicati presenti in PubMed: n= 255

H-Index (Scopus) : 32

Citazioni: 3139

1: Zanella I, Biasiotto G, Castelli F, Calza S, Carriero C, Degli Antoni M, Focà E, **Quiros-Roldan E**. Descriptive modification of inflammatory markers in HIV patients after cART initiation according to gender, smoking habit, CMV infection, BMI and serum lipids. Cytokine. 2021 Jul;143:155547. doi: 10.1016/j.cyto.2021.155547. Epub 2021 Apr 27. PMID: 33931289.

2: Monticelli M, Hay Mele B, Benetti E, Fallerini C, Baldassarri M, Furini S, Frullanti E, Mari F, Andreotti G, Cubellis MV, Renieri A; Gen-Covid Multicenter Study (**including Quiros-Roldan E**). Protective Role of a *TMPRSS2* Variant on Severe COVID-19 Outcome in Young Males and Elderly Women. Genes (Basel). 2021 Apr 19;12(4):596. doi:10.3390/genes12040596. PMID: 33921689; PMCID: PMC8073081.

3: Liu C, Martins AJ, Lau WW, Rachmaninoff N, Chen J, Imberti L, Mostaghimi D, Fink DL, Burbelo PD, Dobbs K, Delmonte OM, Bansal N, Failla L, Sottini A, **Quiros-Roldan E**, Han KL, Sellers BA, Cheung F, Sparks R, Chun TW, Moir S, Lionakis MS; NIAID COVID Consortium; COVID Clinicians, Rossi C, Su HC, Kuhns DB, Cohen JI, Notarangelo LD, Tsang JS. Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19. Cell. 2021 Apr 1;184(7):1836-1857.e22. doi: 10.1016/j.cell.2021.02.018. Epub 2021 Feb 10. PMID: 33713619; PMCID:

PMC7874909.

4: Comelli A, Focà E, Sansone E, Tomasi C, Albini E, **Quiros-Roldan E**, Tomasoni LR, Sala E, Bonfanti C, Caccuri F, Caruso A, De Palma G, Castelli F. Serological Response to SARS-CoV-2 in Health Care Workers Employed in a Large Tertiary Hospital in Lombardy, Northern Italy. *Microorganisms*. 2021 Feb 25;9(3):488. doi: 10.3390/microorganisms9030488. PMID: 33669151; PMCID: PMC7996483.

5: Fallerini C, Daga S, Mantovani S, Benetti E, Picchiotti N, Francisci D, Paciosi F, Schiaroli E, Baldassarri M, Fava F, Palmieri M, Ludovisi S, Castelli F, **Quiros-Roldan E**, Vaghi M, Rusconi S, Siano M, Bandini M, Spiga O, Capitani K, Furini S, Mari F; GEN-COVID Multicenter Study, Renieri A, Mondelli MU, Frullanti E. Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. *Elife*. 2021 Mar 2;10:e67569. doi: 10.7554/eLife.67569. PMID: 33650967; PMCID: PMC7987337.

6: Magro P, Zanella I, Pescarolo M, Castelli F, **Quiros-Roldan E**. Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment. *Biomed J*. 2021 Mar;44(1):43-53. doi: 10.1016/j.bj.2020.11.005. Epub 2020 Nov 10. PMID: 33608241; PMCID: PMC7654234.

7: Bandera A, Lorenzini P, Taramasso L, Cozzi-Lepri A, Lapadula G, Mussini C, Saracino A, Ceccherini-Silberstein F, Puoti M, **Quiros-Roldan E**, Montagnani F, Antinori A, d'Arminio Monforte A, Gori A; Icona Foundation Cohort. The impact of DAA-mediated HCV eradication on CD4⁺ and CD8⁺ T lymphocyte trajectories in HIV/HCV coinfectd patients: Data from the ICONA Foundation Cohort. *J Viral Hepat*. 2021 May;28(5):779-786. doi: 10.1111/jvh.13488. Epub 2021 Mar 11. PMID: 33600068.

8: Malagnino V, Cerva C, Cingolani A, Ceccherini-Silberstein F, Vergori A, Cuomo G, Perno CF, Puoti M, d'Arminio Monforte A, Cozzi-Lepri A, Andreoni M, Sarmati L; ICONA Foundation Study Group. HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients (**including Quiros-Roldan E**) . *Open Forum Infect Dis*.

2020 Nov 18;8(1):ofaa566. doi: 10.1093/ofid/ofaa566. PMID: 33447635; PMCID: PMC7781466.

9: **Quiros-Roldan E**, Porcelli T, Pezzaioli LC, Degli Antoni M, Paghera S, Properzi M, Focà E, Carriero C, Castelli F, Ferlin A. Hypogonadism and liver fibrosis in HIV-infected patients. J Endocrinol Invest. 2021 Jan 29. doi: 10.1007/s40618-021-01512-9. Epub ahead of print. PMID: 33515211.

10: Daga S, Fallerini C, Baldassarri M, Fava F, Valentino F, Doddato G, Benetti E, Furini S, Giliberti A, Tita R, Amitrano S, Bruttini M, Meloni I, Pinto AM, Raimondi F, Stella A, Biscarini F, Picchiotti N, Gori M, Pinoli P, Ceri S, Sanarico M, Crawley FP, Birolo G; GEN-COVID Multicenter Study (**including Quiros-Roldan E**), Renieri A, Mari F, Frullanti E. Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research. Eur J Hum Genet. 2021 May;29(5):745-759. doi: 10.1038/s41431-020-00793-7. Epub 2021 Jan 17. PMID: 33456056; PMCID: PMC7811682.

11: Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, Walker S, Parkinson N, Fourman MH, Russell CD, Furniss J, Richmond A, Gountouna E, Wrobel N, Harrison D, Wang B, Wu Y, Meynert A, Griffiths F, Oosthuyzen W, Kousathanas A, Moutsianas L, Yang Z, Zhai R, Zheng C, Grimes G, Beale R, Millar J, Shih B, Keating S, Zechner M, Haley C, Porteous DJ, Hayward C, Yang J, Knight J, Summers C, Shankar-Hari M, Klenerman P, Turtle L, Ho A, Moore SC, Hinds C, Horby P, Nichol A, Maslove D, Ling L, McAuley D, Montgomery H, Walsh T, Pereira AC, Renieri A; GenOMICC Investigators; ISARIC4C Investigators; COVID-19 Human Genetics Initiative; Investigators; BRACOVID Investigators; Gen-COVID Investigators (**including Quiros-Roldan E**), Shen X, Ponting CP, Fawkes A, Tenesa A, Caulfield M, Scott R, Rowan K, Murphy L, Openshaw PJM, Semple MG, Law A, Vitart V, Wilson JF, Baillie JK. Genetic mechanisms of critical illness in COVID-19. Nature. 2021 Mar;591(7848):92-98. doi: 10.1038/s41586-020-03065-y. Epub 2020 Dec 11. PMID: 33307546.

12: Pezzaioli LC, **Quiros-Roldan E**, Paghera S, Porcelli T, Maffezzoni F, Delbarba A, Degli Antoni M, Cappelli C, Castelli F, Ferlin A. The importance of SHBG and

calculated free testosterone for the diagnosis of symptomatic hypogonadism in HIV-infected men: a single-centre real-life experience. *Infection*. 2021 Apr;49(2):295-303. doi: 10.1007/s15010-020-01558-6. Epub 2020 Dec 8. PMID: 33289905; PMCID: PMC7990869.

13: WHO Solidarity Trial Consortium, **(including Quiros-Roldan E)** Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2. PMID: 33264556; PMCID: PMC7727327.

14: Abers MS, Delmonte OM, Ricotta EE, Fintzi J, Fink DL, de Jesus AAA, Zarembek KA, Alehashemi S, Oikonomou V, Desai JV, Canna SW, Shakoory B, Dobbs K, Imberti L, Sottini A, **Quiros-Roldan E**, Castelli F, Rossi C, Brugnoli D, Biondi A, Bettini LR, D'Angio' M, Bonfanti P, Castagnoli R, Montagna D, Licari A, Marseglia GL, Gliniewicz EF, Shaw E, Kahle DE, Rastegar AT, Stack M, Myint-Hpu K, Levinson SL, DiNubile MJ, Chertow DW, Burbelo PD, Cohen JJ, Calvo KR, Tsang JS; NIAID COVID-19 Consortium, Su HC, Gallin JJ, Kuhns DB, Goldbach-Mansky R, Lionakis MS, Notarangelo LD. An immune-based biomarker signature is associated with mortality in COVID-19 patients. *JCI Insight*. 2021 Jan 11;6(1):e144455. doi: 10.1172/jci.insight.144455. PMID: 33232303; PMCID: PMC7821609.

15: Maffezzoni F, Porcelli T, Delbarba A, Pezzaioli LC, Properzi M, Cappelli C, Castelli F, **Quiros-Roldan ME**, Ferlin A. Hypogonadism and bone health in men with

HIV. Lancet HIV. 2020 Nov;7(11):e782-e790. doi: 10.1016/S2352-3018(20)30236-8. PMID: 33128905.

16: **Quiros-Roldan E**, Magro P, Carriero C, Chiesa A, El Hamad I, Tratta E, Fazio R, Formenti B, Castelli F. Consequences of the COVID-19 pandemic on the continuum of care in a cohort of people living with HIV followed in a single center of Northern Italy. AIDS Res Ther. 2020 Oct 4;17(1):59. doi: 10.1186/s12981-020-00314-y. PMID: 33012282; PMCID: PMC7533114.

17: Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K, Philippot Q, Rosain J, Béziat V, Manry J, Shaw E, Haljasmägi L, Peterson P, Lorenzo L, Bizien L, Trouillet-Assant S, Dobbs K, de Jesus AA, Belot A, Kallaste A, Catherinot E, Tandjaoui-Lambiotte Y, Le Pen J, Kerner G, Bigio B, Seeleuthner Y, Yang R, Bolze A, Spaan AN, Delmonte OM, Abers MS, Aiuti A, Casari G, Lampasona V, Piemonti L, Ciceri F, Bilguvar K, Lifton RP, Vasse M, Smadja DM, Migaud M, Hadjadj J, Terrier B, Duffy D, Quintana-Murci L, van de Beek D, Roussel L, Vinh DC, Tangye SG, Haerynck F, Dalmau D, Martinez-Picado J, Brodin P, Nussenzweig MC, Boisson-Dupuis S, Rodríguez-Gallego C, Vogt G, Mogensen TH, Oler AJ, Gu J, Burbelo PD, Cohen JI, Biondi A, Bettini LR, D'Angio M, Bonfanti P, Rossignol P, Mayaux J, Rieux-Laucat F, Husebye ES, Fusco F, Ursini MV, Imberti L, Sottini A, Paghera S, **Quiros-Roldan E**, Rossi C, Castagnoli R, Montagna D, Licari A, Marseglia GL, Duval X, Ghosn J; HGID Lab; NIAID-USUHS Immune Response to COVID Group; COVID Clinicians; COVID-STORM Clinicians; Imagine COVID Group; French COVID Cohort Study Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort, Tsang JS, Goldbach-Mansky R, Kisand K, Lionakis MS, Puel A, Zhang SY, Holland SM, Gorochoff G, Jouanguy E, Rice CM, Cobat A, Notarangelo LD, Abel L, Su HC, Casanova JL. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 Oct 23;370(6515):eabd4585. doi: 10.1126/science.abd4585. Epub 2020 Sep 24. PMID: 32972996; PMCID: PMC7857397.

18: Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, Ogishi M, Sabli IKD, Hodeib S, Korol C, Rosain J, Bilguvar K, Ye J, Bolze A, Bigio B, Yang R, Arias AA, Zhou Q, Zhang Y, Onodi F, Korniotis S, Karpf L, Philippot Q, Chbihi

M, Bonnet-Madin L, Dorgham K, Smith N, Schneider WM, Razooky BS, Hoffmann HH, Michailidis E, Moens L, Han JE, Lorenzo L, Bizien L, Meade P, Neehus AL, Ugurbil AC, Corneau A, Kerner G, Zhang P, Rapaport F, Seeleuthner Y, Manry J, Masson C, Schmitt Y, Schlüter A, Le Voyer T, Khan T, Li J, Fellay J, Roussel L, Shahrooei M, Alosaimi MF, Mansouri D, Al-Saud H, Al-Mulla F, Almourfi F, Al-Muhsen SZ, Alsohime F, Al Turki S, Hasanato R, van de Beek D, Biondi A, Bettini LR, D'Angio' M, Bonfanti P, Imberti L, Sottini A, Paghera S, **Quiros-Roldan E**, Rossi C, Oler AJ, Tompkins MF, Alba C, Vandernoot I, Goffard JC, Smits G, Migeotte I, Haerynck F, Soler-Palacin P, Martin-Nalda A, Colobran R, Morange PE, Keles S, Çölkesen F, Ozcelik T, Yasar KK, Senoglu S, Karabela ŞN, Rodríguez-Gallego C, Novelli G, Hraiech S, Tandjaoui-Lambiotte Y, Duval X, Laouénan C; COVID-STORM Clinicians; COVID Clinicians; Imagine COVID Group; French COVID Cohort Study Group; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort; NIAID-USUHS/TAGC COVID Immunity Group, Snow AL, Dalgard CL, Milner JD,

Vinh DC, Mogensen TH, Marr N, Spaan AN, Boisson B, Boisson-Dupuis S, Bustamante J, Puel A, Ciancanelli MJ, Meyts I, Maniatis T, Soumelis V, Amara A, Nussenzweig M, García-Sastre A, Krammer F, Pujol A, Duffy D, Lifton RP, Zhang SY, Gorochov G, Béziat V, Jouanguy E, Sancho-Shimizu V, Rice CM, Abel L, Notarangelo LD, Cobat A, Su HC, Casanova JL. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science*. 2020 Oct 23;370(6515):eabd4570. doi: 10.1126/science.abd4570. Epub 2020 Sep 24. PMID: 32972995; PMCID: PMC7857407.

19: Snyder TM, Gittelman RM, Klinger M, May DH, Osborne EJ, Taniguchi R, Zahid HJ, Kaplan IM, Dines JN, Noakes MN, Pandya R, Chen X, Elasady S, Svejnova E, Ebert P, Pesesky MW, De Almeida P, O'Donnell H, DeGottardi Q, Keitany G, Lu J, Vong A, Elyanow R, Fields P, Greissl J, Baldo L, Semprini S, Cerchione C, Mazza M, Delmonte OM, Dobbs K, Carreño-Tarragona G, Barrio S, Imberti L, Sottini A, **Quiros-Roldan E**, Rossi C, Biondi A, Bettini LR, D'Angio M, Bonfanti P, Tompkins MF, Alba C, Dalgard C, Sambri V, Martinelli G, Goldman JD, Heath JR, Su HC, Notarangelo LD, Martinez-Lopez J, Carlson JM, Robins HS. Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels. *medRxiv* [Preprint]. 2020 Aug 4:2020.07.31.20165647. doi: 10.1101/2020.07.31.20165647. PMID: 32793919; PMCID: PMC7418734.

- 20: Benetti E, Tita R, Spiga O, Ciolfi A, Birolo G, Bruselles A, Doddato G, Giliberti A, Marconi C, Musacchia F, Pippucci T, Torella A, Trezza A, Valentino F, Baldassarri M, Brusco A, Asselta R, Bruttini M, Furini S, Seri M, Nigro V, Matullo G, Tartaglia M, Mari F; GEN-COVID Multicenter Study (**including Quiros-Roldan E**) , Renieri A, Pinto AM. ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. Eur J Hum Genet. 2020 Nov;28(11):1602-1614. doi: 10.1038/s41431-020-0691-z. Epub 2020 Jul 17. PMID: 32681121; PMCID: PMC7366459.
- 21: Moratto D, Chiarini M, Giustini V, Serana F, Magro P, Roccaro AM, Imberti L, Castelli F, Notarangelo LD, **Quiros-Roldan E**. Flow Cytometry Identifies Risk Factors and Dynamic Changes in Patients with COVID-19. J Clin Immunol. 2020 Oct;40(7):970-973. doi: 10.1007/s10875-020-00806-6. Epub 2020 Jun 27. PMID: 32594342; PMCID: PMC7320913.
- 22: Moratto D, Giacomelli M, Chiarini M, Savarè L, Saccani B, Motta M, Timpano S, Poli P, Paghera S, Imberti L, Cannizzo S, **Quiros-Roldan E**, Marchetti G, Badolato R. Immune response in children with COVID-19 is characterized by lower levels of T-cell activation than infected adults. Eur J Immunol. 2020 Sep;50(9):1412-1414. doi: 10.1002/eji.202048724. Epub 2020 Jul 29. PMID: 32592406; PMCID: PMC7361574.
- 23: Taramasso L, Fabbiani M, Nozza S, De Benedetto I, Bruzzesi E, Mastrangelo A, Pinnetti C, Calcagno A, Ferrara M, Bozzi G, Focà E, **Quiros-Roldan E**, Ripamonti D, Campus M, Celesia BM, Torti C, Cosco L, Di Biagio A, Rusconi S, Marchetti G, Mussini C, Gulminetti R, Cingolani A, d'Ettorre G, Madeddu G, Franco A, Orofino G, Squillace N, Muscatello A, Gori A, Antinori A, Tambussi G, Bandera A; INACTION study group. Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort. HIV Med. 2020 Sep;21(8):523-535. doi: 10.1111/hiv.12885. Epub 2020 Jun 24. PMID: 32578947.

24: **Quiros-Roldan E**, Properzi M, Paghera S, Raffetti E, Castelli F, Imberti L. Factors associated with immunosenescence during early adulthood in HIV-infected patients after durable efficient combination antiretroviral therapy. Sci Rep. 2020 Jun 22;10(1):10057. doi: 10.1038/s41598-020-67100-8. PMID: 32572110; PMCID: PMC7308364.

25: **Quiros-Roldan E**, Biasiotto G, Zanella I. Letter to the Editor on "Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev". Cytokine Growth Factor Rev. 2020 Aug;54:1-2. doi: 10.1016/j.cytogfr.2020.06.002. Epub 2020 Jun 4. PMID: 32522400; PMCID: PMC7272164.

26: **Quiros-Roldan E**, Gardini G, Properzi M, Ferraresi A, Carella G, Marchi A, Malagoli A, Focà E, Castelli F. Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV. Pharmacogenet Genomics. 2020 Oct;30(8):167-174. doi: 10.1097/FPC.0000000000000409. PMID: 32453265.

27: **Quiros Roldan E**, Biasiotto G, Magro P, Zanella I. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? Pharmacol Res. 2020 Aug;158:104904. doi: 10.1016/j.phrs.2020.104904. Epub 2020 May 13. PMID: 32430286; PMCID: PMC7217799.

28: Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, Maffei C, Possenti S, Piva S, Latronico N, Focà E, Castelli F, Gaggia P, Movilli E, Bove S, Malberti F, Farina M, Bracchi M, Costantino EM, Bossini N, Gaggiotti M, Scolari F; Brescia Renal COVID Task Force (**including Quiros-Roldan E**). Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy. Kidney Int Rep. 2020 Apr 4;5(5):580-585. doi: 10.1016/j.ekir.2020.04.001. PMID: 32292866; PMCID: PMC7128395.

29: Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green

G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, **Quiros-Roldan E**, Studemeister A, Redinski J, Ahmed S, Bennett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *N Engl J Med*. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10. PMID: 32275812; PMCID: PMC7169476.

30: Muscatello A, Nozza S, Fabbiani M, De Benedetto I, Ripa M, Dell'acqua R, Antinori A, Pinnetti C, Calcagno A, Ferrara M, Focà E, **Quiros-Roldan E**, Ripamonti D, Campus M, Maurizio Celesia B, Torti C, Cosco L, Di Biagio A, Rusconi S, Marchetti G, Mussini C, Gulminetti R, Cingolani A, D'ettorre G, Madeddu G, Franco A, Orofino G, Squillace N, Gori A, Tambussi G, Bandera A; Inaction Study Group.. Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study. *Pathog Immun*. 2020 Feb 24;5(1):8-33. doi: 10.20411/pai.v5i1.341. PMID: 32258852; PMCID: PMC7104556.

31: Celotti A, Gargiulo F, **Quiros-Roldan E**, Properzi M, De Francesco MA, Coletto D, Caccuri F, Izzo I, Caruso A, Castelli F, Focà E. Presence of V72I, G123S and R127K Integrase Inhibitor polymorphisms could reduce ART effectiveness: a retrospective longitudinal study. *HIV Res Clin Pract*. 2020 Feb;21(1):24-33. doi: 10.1080/25787489.2020.1734753. Epub 2020 Mar 6. PMID: 32141388.

32: Lorenzin G, Gargiulo F, Caruso A, Caccuri F, Focà E, Celotti A, **Quiros-Roldan E**, Izzo I, Castelli F, De Francesco MA. Prevalence of Non-B HIV-1 Subtypes in North Italy and Analysis of Transmission Clusters Based on Sequence Data Analysis. *Microorganisms*. 2019 Dec 23;8(1):36. doi: 10.3390/microorganisms8010036. PMID: 31878069; PMCID: PMC7022943.

- 33: d'Arminio Monforte A, Tavelli A, Cozzi-Lepri A, Castagna A, Passerini S, Francisci D, Saracino A, Maggiolo F, Lapadula G, Girardi E, Perno CF, Antinori A; Icona Foundation Study Group (**including Quiros-Roldan E**). Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort. *J Antimicrob Chemother*. 2020 Mar 1;75(3):681-689. doi: 10.1093/jac/dkz512. PMID: 31865395.
- 34: Properzi M, Della Giustina T, Mentasti S, Castelli F, Chiesa A, Gregori N, **Quiros-Roldan E**. Low prevalence of symptomatic thyroid diseases and thyroid cancers in HIV-infected patients. *Sci Rep*. 2019 Dec 19;9(1):19459. doi: 10.1038/s41598-019-56032-7. PMID: 31857648; PMCID: PMC6923431.
- 35: **Quiros-Roldan E**, Castelli F, Bonito A, Vezzoli M, Calza S, Biasiotto G, Zanella I; Inflammation in HIV Study Group. The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naïve patients. *Cytokine*. 2020 Feb;126:154884. doi: 10.1016/j.cyto.2019.154884. Epub 2019 Oct 26. PMID: 31670006.
- 36: Paghera S, **Quiros-Roldan E**, Sottini A, Properzi M, Castelli F, Imberti L. Lymphocyte homeostasis is maintained in perinatally HIV-infected patients after three decades of life. *Immun Ageing*. 2019 Oct 13;16:26. doi: 10.1186/s12979-019-0166-7. PMID: 31636688; PMCID: PMC6791008.
- 37: Shanyinde M, Girardi E, Puoti M, De Luca A, Sighinolfi L, Caterina UF, Caramello P, Lampe FC, D'Arminio Monforte A, Cozzi-Lepri A; ICONA Foundation Study Group (**including Quiros-Roldan E**). Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? *BMC Public Health*. 2019 Oct 15;19(1):1291. doi: 10.1186/s12889-019-7608-1. PMID: 31615542; PMCID: PMC6794785.
- 38: Taramasso L, Lorenzini P, Di Biagio A, Lichtner M, Marchetti G, Rossotti R, Lapadula G, Cozzi-Lepri A, Vichi F, Antinori A, Bonora S, d'Arminio Monforte A; ICONA Foundation Study Group (**including Quiros-Roldan E**). Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the

ICONA cohort. J Antimicrob Chemother. 2019 Nov 1;74(11):3295-3304. doi: 10.1093/jac/dkz353. PMID: 31504633.

39: Comelli A, Izzo I, Donato F, Celotti A, Focà E, Pezzoli C, Castelli F, **Quiros-Roldan E**. Disengagement and reengagement of HIV continuum of care in a single center cohort in northern Italy. HIV Res Clin Pract. 2019 Feb;20(1):1-11. doi: 10.1080/15284336.2019.1595887. Epub 2019 Apr 25. PMID: 31303148.

40: Rohner E, Bütikofer L, Schmidlin K, Sengayi M, Maskew M, Giddy J, Taghavi K, Moore RD, Goedert JJ, Gill MJ, Silverberg MJ, D'Souza G, Patel P, Castilho JL, Ross J, Sohn A, Bani-Sadr F, Taylor N, Pappas M, Bonnet F, Verbon A, Vehreschild JJ, Post FA, Sabin C, Mocroft A, Dronda F, Obel N, Grabar S, Spagnuolo V, **Quiros-Roldan E**, Mussini C, Miro JM, Meyer L, Hasse B, Konopnicki D, Roca B, Barger D, Clifford GM, Franceschi S, Egger M, Bohlius J. Cervical cancer risk in women living with HIV across four continents: A multicohort study. Int J Cancer. 2020 Feb 1;146(3):601-609. doi: 10.1002/ijc.32260. Epub 2019 Jun 19. PMID: 31215037; PMCID: PMC6898726.

41: Gianotti N, Lorenzini P, Cozzi-Lepri A, De Luca A, Madeddu G, Sighinolfi L, Pinnetti C, Santoro C, Meraviglia P, Mussini C, Antinori A, d'Arminio Monforte A; ICONA Foundation Study Group (**including Quiros-Roldan E**). Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm³ and HIV-RNA >5 log₁₀ copies/mL. J Antimicrob Chemother. 2019 Sep 1;74(9):2732-2741. doi: 10.1093/jac/dkz237. PMID: 31173639.

42: Castagna A, Rusconi S, Gulminetti R, Bonora S, Mazzola G, **Quiros-Roldan ME**, De Socio GV, Ladisa N, Carosella S, Cattelan A, Di Giambenedetto S, Mena M, Poli A, Galli L, Riva A; DAU Study Group. Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy. AIDS. 2019 Jun 1;33(7):1256-1260. doi: 10.1097/QAD.0000000000002188. PMID: 30870194.

43: Mondi A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, Marchetti G, Antinori A,

d'Arminio Monforte A; Icona Foundation Study Group (**including Quiros-Roldan E**). Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. J Int AIDS Soc. 2019 Jan;22(1):e25227. doi: 10.1002/jia2.25227. PMID: 30663278; PMCID: PMC6340053.

44: **Quiros-Roldan E**, Pezzoli MC, Berlendis M, Raffetti E, Ferraresi A, Properzi M, Rodari P, Castelli F. A COPD Case-Finding Program in a Large Cohort of HIV-Infected Persons. Respir Care. 2019 Feb;64(2):169-175. doi: 10.4187/respcare.06247. Epub 2018 Dec 11. PMID: 30538159.

45: Properzi M, Magro P, Castelli F, **Quiros-Roldan E**. Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults. Expert Rev Anti Infect Ther. 2018 Dec;16(12):877-887. doi: 10.1080/14787210.2018.1544491. Epub 2018 Nov 14. PMID: 30392419.

46: Ceccherini-Silberstein F, Cozzi Lepri A, Alteri C, Merlini E, Surdo M, Marchetti G, Capobianchi MR, De Luca A, Gianotti N, Viale P, Andreoni M, Antinori A, Perno CF, d'Arminio Monforte A; ICONA Foundation Study Group (**including Quiros-Roldan E**). Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. J Antimicrob Chemother. 2018 Dec 1;73(12):3460-3470. doi: 10.1093/jac/dky350. PMID: 30247724.

47: AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (**including Quiros-Roldan E**). Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS. 2018 Nov 28;32(18):2777-2786. doi: 10.1097/QAD.0000000000002003. PMID: 30234606; PMCID: PMC6237186.

48: **Quiros-Roldan E**, Properzi M, Amadasi S, Raffetti E, Ferraresi A, Biasi L, Focà E, Castelli F. Prognostic role of inflammatory biomarkers in HIV-infected patients with a first diagnosis of hepatocellular carcinoma: A single-center study. J Med Virol. 2019 Feb;91(2):241-248. doi: 10.1002/jmv.25317. Epub 2018 Oct 31. PMID: 30216474.

49: **Quiros-Roldan E**, Zanini B, Ferraresi A, Castellano M, Giustini V, Sottini A, Castelli F, Imberti L. Peripheral loss of regulatory T cells and polyautoimmunity in an HIV-infected patient. *Int J STD AIDS*. 2018 Nov;29(13):1345-1347. doi: 10.1177/0956462418785997. Epub 2018 Jul 27. PMID: 30049261.

50: Saracino A, Zaccarelli M, Lorenzini P, Bandera A, Marchetti G, Castelli F, Gori A, Girardi E, Mussini C, Bonfanti P, Ammassari A, d'Arminio Monforte A; Icona Foundation Study Group (**including Quiros-Roldan E**). Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. *BMC Public Health*. 2018 Jul 13;18(1):870. doi: 10.1186/s12889-018-5804-z. PMID: 30005709; PMCID: PMC6044027.

51: **Quiros-Roldan E**, Magro P, Raffetti E, Izzo I, Borghetti A, Lombardi F, Saracino A, Maggiolo F, Castelli F; MASTER Cohort. Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015. *BMC Infect Dis*. 2018 Jun 25;18(1):285. doi: 10.1186/s12879-018-3198-2. PMID: 29940869; PMCID: PMC6020212.

52: Taramasso L, Di Biagio A, Maggiolo F, Tavelli A, Lo Caputo S, Bonora S, Zaccarelli M, Caramello P, Costantini A, Viscoli C, d'Arminio Monforte A, Cozzi-Lepri A; Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study Group (**including Quiros-Roldan E**). First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. *HIV Med*. 2018 May 30. doi: 10.1111/hiv.12628. Epub ahead of print. PMID: 29846042.

53: Mussini C, Lorenzini P, Cozzi-Lepri A, Marchetti G, Rusconi S, Gori A, Nozza S, Lichtner M, Antinori A, Cossarizza A, d'Arminio Monforte A; Icona Foundation Study Group (**including Quiros-Roldan E**). Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. *BMC Med*. 2018 May 29;16(1):79. doi: 10.1186/s12916-018-1046-2. PMID: 29807541; PMCID:

PMC5972434.

54: Belmonti S, Lombardi F, **Quiros-Roldan E**, Latini A, Castagna A, Borghetti A, Baldin G, Ciccullo A, Cauda R, De Luca A, Di Giambenedetto S; ATLAS-M Study Group. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. J Antimicrob Chemother. 2018 Jul 1;73(7):1949-1954. doi: 10.1093/jac/dky125. PMID: 29788156.

55: Focà E, Calcagno A, Bonito A, Cusato J, Domenighini E, D'Avolio A, **Quiros Roldan E**, Trentini L, Castelnuevo F, Di Perri G, Castelli F, Bonora S. Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. Antimicrob Agents Chemother. 2018 Jun 26;62(7):e00309-18. doi: 10.1128/AAC.00309-18. PMID: 29760129; PMCID: PMC6021630.

56: Fabbiani M, Gagliardini R, Ciccarelli N, **Quiros Roldan E**, Latini A, d'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Del Pin B, Lombardi F, D'Avino A, Focà E, Colafigli M, Cauda R, Di Giambenedetto S, De Luca A; ATLAS-M Study Group. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964. doi: 10.1093/jac/dky123. PMID: 29668978.

57: De Francesco MA, Izzo I, Properzi M, Gargiulo F, Caccuri F, **Quiros-Roldan E**, Castelli F, Caruso A, Focà E. Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience. AIDS Res Hum Retroviruses. 2018 Jul;34(7):570-574. doi: 10.1089/AID.2018.0006. Epub 2018 May 9. PMID: 29631420.

58: Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data

Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group (**Quiros-Roldan E**). Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. J Int AIDS Soc. 2018 Mar;21(3):e25083. doi: 10.1002/jia2.25083.

PMID: 29509305; PMCID: PMC5839235.

59: **Quiros-Roldan E**, Castelli F, Lanza P, Pezzoli C, Vezzoli M; Inflammation in HIV Study Group, Biasiotto G, Zanella I. The impact of antiretroviral therapy on iron homeostasis and inflammation markers in HIV-infected patients with mild anemia. J Transl Med. 2017 Dec 19;15(1):256. doi: 10.1186/s12967-017-1358-6. PMID: 29258550; PMCID: PMC5735890.

60: Izzo I, **Quiros-Roldan E**, Saccani B, Chiari E, Casari S, Focà E, Pezzoli MC, Forleo MA, Bonito A, Badolato R, Dotta L, Castelli F. Perinatally HIV-Infected Youths After Transition from Pediatric to Adult Care, a Single-Center Experience from Northern Italy. AIDS Res Hum Retroviruses. 2018 Mar;34(3):241-243. doi: 10.1089/AID.2017.0120. Epub 2017 Nov 17. PMID: 29061072.

61: Smit M, Cassidy R, Cozzi-Lepri A, **Quiros-Roldan E**, Girardi E, Mammone A, Antinori A, Saracino A, Bai F, Rusconi S, Magnani G, Castelli F, Hsue P, d'Arminio Monforte A, Hallett TB. Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. PLoS One. 2017 Oct 23;12(10):e0186638. doi: 10.1371/journal.pone.0186638. PMID: 29059202; PMCID: PMC5653300.

62: Focà E, Calcagno A, Bonito A, Simiele M, Domenighini E, D'Avolio A, **Quiros Roldan E**, Trentini L, Casari S, Di Perri G, Castelli F, Bonora S. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. J Antimicrob Chemother. 2017 Nov 1;72(11):3163-3166. doi: 10.1093/jac/dkx274. PMID: 28961777.

63: **Quiros Roldan E**, Brianese N, Raffetti E, Focà E, Pezzoli MC, Bonito A, Ferraresi A, Lanza P, Porcelli T, Castelli F. Comparison between the gold standard DXA with calcaneal quantitative ultrasound based-strategy (QUS) to

detect osteoporosis in an HIV infected cohort. *Braz J Infect Dis*. 2017 Nov-Dec;21(6):581-586. doi: 10.1016/j.bjid.2017.08.003. Epub 2017 Sep 23. PMID: 28950107.

64: AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord (**including Quiros-Roldan E**). Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. *Clin Infect Dis*. 2017 Oct 15;65(8):1316-1326. doi: 10.1093/cid/cix480. PMID: 28531260; PMCID: PMC5850623.

65: Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A; Icona Foundation Study Group (**including Quiros-Roldan E**). Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤ 50 cp/mL. *Infection*. 2017 Aug;45(4):521-528. doi: 10.1007/s15010-017-1018-z. Epub 2017 May 5. PMID: 28477212.

66: Izzo I, **Quiros-Roldan E**, Casari S, Gargiulo F, Caruso A, Castelli F. Characteristics and Outcome of a Cohort of HIV-1 Non-B Subtype-Infected Patients After a 10-Year Follow-up Period: A Single Centre Experience. *J Acquir Immune Defic Syndr*. 2017 May 1;75(1):e23-e24. doi: 10.1097/QAI.0000000000001260. PMID: 28399559.

67: Lombardi F, Belmonti S, **Quiros-Roldan E**, Latini A, Castagna A, D'Ettorre G, Gagliardini R, Fabbiani M, Cauda R, De Luca A, Di Giambenedetto S; AtLaS-M Study Group. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. *J Antimicrob Chemother*. 2017 Jul 1;72(7):2055-2059. doi: 10.1093/jac/dkx068. PMID: 28333353.

68: Postorino MC, Prosperi M, Focà E, **Quiros-Roldan E**, Di Filippo E, Maggiolo F, Borghetti A, Ladisa N, Di Pietro M, Gori A, Sighinolfi L, Pan A, Mazzini N, Torti C. Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the

Italian MASTER cohort. BMC Infect Dis. 2017 Mar 15;17(1):212. doi: 10.1186/s12879-017-2322-z. PMID: 28298195; PMCID: PMC5353877.

69: Raffetti E, Donato F, Casari S, Castelnuovo F, Sighinolfi L, Bandera A, Maggiolo F, Ladisa N, di Pietro M, Fornabaio C, Digiambenedetto S, **Quiros-Roldan E**. Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort study. BMC Infect Dis. 2017 Mar 7;17(1):193. doi: 10.1186/s12879-017-2280-5. PMID: 28264665; PMCID: PMC5339992.

70: Di Giambenedetto S, Fabbiani M, **Quiros Roldan E**, Latini A, D'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Di Pietro M, Mondì A, Ciccarelli N, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R; Atlas-M Study Group. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017 Apr 1;72(4):1163-1171. doi: 10.1093/jac/dkw557. PMID: 28093483.

71: Puoti M, Lorenzini P, Cozzi-Lepri A, Gori A, Mastroianni C, Rizzardini G, Mazzarello G, Antinori A, d'Arminio Monforte A, Girardi E; Icona Foundation Study Group (**including Quiros-Roldan E**) . Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. Clin Microbiol Infect. 2017 Apr;23(4):267.e1-267.e4. doi: 10.1016/j.cmi.2016.12.003. Epub 2016 Dec 9. PMID: 27956268.

72: **Quiros-Roldan E**, Magoni M, Raffetti E, Donato F, Scarcella C, Paraninfo G, Castelli F. The burden of chronic diseases and cost-of-care in subjects with HIV infection in a Health District of Northern Italy over a 12-year period compared to that of the general population. BMC Public Health. 2016 Nov 9;16(1):1146. doi: 10.1186/s12889-016-3804-4. PMID: 27829390; PMCID: PMC5103392.

73: Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord (**including Quiros-Roldan E**) . Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since

Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies. Clin Infect Dis. 2016 Nov 15;63(10):1373-1379. doi: 10.1093/cid/ciw562. Epub 2016 Aug 17. PMID: 27535953; PMCID: PMC5091347.

74: Wang Q, De Luca A, Smith C, Zangerle R, Sambatakou H, Bonnet F, Smit C, Schommers P, Thornton A, Berenguer J, Peters L, Spagnuolo V, Ammassari A, Antinori A, **Quiros-Roldan E**, Mussini C, Miro JM, Konopnicki D, Fehr J, Campbell MA, Termote M, Bucher HC; Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study. Ann Intern Med. 2017 Jan 3;166(1):9-17. doi: 10.7326/M16-0240. Epub 2016 Oct 18. PMID: 27750294.

75: Postorino MC, **Quiros-Roldan E**, Maggiolo F, Di Giambenedetto S, Ladisa N, Lapadula G, Lorenzotti S, Sighinolfi L, Castelnuevo F, Di Pietro M, Gotti D, Mazzini N, Torti C; MASTER Study Group. Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function. Open AIDS J. 2016 Jul 15;10:136-43. doi: 10.2174/1874613601610010136. PMID: 27563366; PMCID: PMC4968049.

76: **Quiros-Roldan E**, Raffetti E, Castelli F, Focà E, Castelnuevo F, Di Pietro M, Gagliardini R, Gori A, Saracino A, Fornabaio C, Sighinolfi L, Di Filippo E, Maggiolo F, Donato F. Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study. J Antimicrob Chemother. 2016 Dec;71(12):3519-3527. doi: 10.1093/jac/dkw307. Epub 2016 Aug 19. PMID: 27543658.

77: **Quiros-Roldan E**, Raffetti E, Focà E, Brianese N, Ferraresi A, Parainfo G, Pezzoli MC, Bonito A, Magoni M, Scarcella C, Castelli F. Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012. AIDS Care. 2016 Dec;28(12):1551-1558. doi: 10.1080/09540121.2016.1198750. Epub 2016 Jun 20.

PMID: 27321070.

78: Focà E, Fabbiani M, Prosperi M, **Quiros Roldan E**, Castelli F, Maggiolo F, Di Filippo E, Di Giambenedetto S, Gagliardini R, Saracino A, Di Pietro M, Gori A, Sighinolfi L, Pan A, Postorino MC, Torti C; Italian MASTER Cohort. Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study. *Medicine (Baltimore)*. 2016 Jul;95(29):e4091. doi: 10.1097/MD.00000000000004091. PMID: 27442636; PMCID: PMC5265753.

79: Squillace N, Lorenzini P, Lapadula G, Bandera A, Cozzi-Lepri A, Rusconi S, Puoti M, Castagna A, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group (**including Quiros-Roldan E**). Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. *J Antimicrob Chemother*. 2016 Sep;71(9):2663-9. doi: 10.1093/jac/dkw185. Epub 2016 Jun 5. PMID: 27272727.

80: **Quiros-Roldan E**, Raffetti E, Donato F, Magoni M, Pezzoli C, Ferraresi A, Brianese N, Castelnovo F, Focà E, Castelli F. Neutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV-Infected Patients: A Population-Based Cohort Study. *PLoS One*. 2016 May 5;11(5):e0154900. doi: 10.1371/journal.pone.0154900. PMID: 27148878; PMCID: PMC4858273.

81: Focà E, Magro P, Motta D, Compostella S, Casari S, Bonito A, Brianese N, Ferraresi A, Rodari P, Pezzoli MC, **Quiros-Roldan E**, Castelli F. Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy. *Int J Mol Sci*. 2016 Mar 24;17(4):434. doi: 10.3390/ijms17040434. PMID: 27023519; PMCID: PMC4848890.

82: Di Biagio A, Cozzi-Lepri A, Prinapori R, Angarano G, Gori A, Quirino T, De Luca A, Costantini A, Mussini C, Rizzardini G, Castagna A, Antinori A, d'Arminio Monforte A; ICONA Foundation Study Group (**including Quiros-Roldan E**). Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized

Therapy. J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):263-71. doi: 10.1097/QAI.0000000000000849. PubMed PMID: 26871881; PubMed Central PMCID: PMC4770376.

83: Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study (**including Quiros-Roldan E**). Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17. PubMed PMID: 26762990.

84: Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation Study Group(**including Quiros-Roldan E**) . Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. PLoS One. 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877. eCollection 2015. PubMed PMID: 26640953; PubMed Central PMCID: PMC4671690.

85: Saracino A, Lorenzini P, Lo Caputo S, Girardi E, Castelli F, Bonfanti P, Rusconi S, Caramello P, Abrescia N, Mussini C, Monno L, d'Arminio Monforte A; ICONA Foundation Study Group (**including Quiros-Roldan E**). Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. Clin Microbiol Infect. 2016 Mar;22(3):288.e1-8. doi: 10.1016/j.cmi.2015.10.026. Epub 2015 Nov 10. PubMed PMID: 26551839.

86: Torti C, Raffetti E, Donato F, Castelli F, Maggiolo F, Angarano G, Mazzotta F, Gori A, Sighinolfi L, Pan A, Cauda R, Scalzini A, **Quiros-Roldan E**, Nasta P, Gregis G, Benatti S, Digiambenedetto S, Ladisa N, Giralda M, Saracino A, Castelnovo F, Di Pietro M, Lo Caputo S, Lapadula G, Costarelli S, Lorenzotti S, Mazzini N, Paraninfo G, Casari S, Focà E, Pezzoli C, Fabbiani M, Monno L, Pierotti P, Ble C, Leone S, Postorino MC, Fornabaio C, Zacchi F, Zoncada A, Carosi G. Cohort Profile: Standardized Management of Antiretroviral Therapy

Cohort (MASTER Cohort). Int J Epidemiol. 2015 Oct 7. pii: dyv192. [Epub ahead of print] PubMed PMID: 26445966.

87: Raffetti E, Donato F, Castelli F, Maggiolo F, Carosi G, **Quiros-Roldan E**. The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study. Infect Agent Cancer. 2015 Oct 5;10:34. doi: 10.1186/s13027-015-0032-y. eCollection 2015. PubMed PMID: 26442127; PubMed Central PMCID: PMC4593208.

88: Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastrì E, Cingolani A, Lichtner M, Antinori A, Gori A, d'Arminio Monforte A; Ico Foundation Study Group (**including Quiros-Roldan E**). CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015 Mar;2(3):e98-106. doi: 10.1016/S2352-3018(15)00006-5. Epub 2015 Feb 6. PubMed PMID: 26424550.

89: Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group (**including Quiros-Roldan E**). Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016 Apr;17(4):255-68. doi: 10.1111/hiv.12294. Epub 2015 Jul 28. PubMed PMID: 26216031.

90: Raffetti E, Donato F, Pezzoli C, Digiambenedetto S, Bandera A, Di Pietro M, Di Filippo E, Maggiolo F, Sighinolfi L, Fornabaio C, Castelnuovo F, Ladisa N, Castelli F, **Quiros Roldan E**. Systemic Inflammation-Based Biomarkers and Survival in HIV-Positive Subject With Solid Cancer in an Italian Multicenter Study. J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):585-92. doi: 10.1097/QAI.0000000000000682. PubMed PMID: 26167619.

91: Cingolani A, Zona S, Girardi E, Cozzi-Lepri A, Monno L, **Quiros Roldan E**, Guaraldi G, Antinori A, D'Arminio Monforte A, Marcotullio S; Community-Oriented Study Group of the Ico Foundation Study Group. Incidence and factors associated

with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort. HIV Med. 2015 Aug;16(7):412-20. doi: 10.1111/hiv.12226. Epub 2015 May 11. PubMed PMID: 25959419; PubMed Central PMCID: PMC4682467.

92: Bandera A, Gori A, Sabbatini F, Madeddu G, Bonora S, Libertone R, Mastroianni C, Bonfanti P, d'Arminio Monforte A, Cozzi-Lepri A; Icona Foundation Study Group (**including Quiros-Roldan E**). Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. PLoS One. 2015 May 1;10(5):e0124252. doi: 10.1371/journal.pone.0124252. eCollection 2015. PubMed PMID: 25933346; PubMed Central PMCID: PMC4416769.

93: Raffetti E, Donato F, Castelnuovo F, Ladisa N, Paraninfo G, Di Filippo E, Segala D, Cologni G, Bandera A, Zacchi F, Digiambenedetto S, Di Pietro M, Castelli F, **Quiros-Roldan E**; MASTER Cohort. The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study. J Transl Med. 2015 Mar 14;13:89. doi: 10.1186/s12967-015-0446-8. PubMed PMID: 25886534; PubMed Central PMCID: PMC4562103.

94: Raffetti E, Albini L, Gotti D, Segala D, Maggiolo F, di Filippo E, Saracino A, Ladisa N, Lapadula G, Fornabaio C, Castelnuovo F, Casari S, Fabbiani M, Pierotti P, Donato F, **Quiros-Roldan E**; MASTER Cohort. Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study. BMC Public Health. 2015 Mar 12;15:235. doi: 10.1186/s12889-015-1565-0. PubMed PMID: 25884678; PubMed Central PMCID: PMC4364101.

95: Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group (**including Quiros-Roldan E**); Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Development and validation of a risk score for chronic kid-

ney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar. PubMed PMID: 25826420; PubMed Central PMCID: PMC4380415.

96: Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group (**including Quiros-Roldan E**). Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523. PubMed PMID: 25763785.

97: Lapadula G, Costarelli S, Chatenoud L, Castelli F, Astuti N, Di Giambenedetto S, **Quiros-Roldan E**, Sighinolfi L, Ladisa N, Di Pietro M, Zoncada A, Di Filippo E, Gori A, Nasta P, Torti C; Italian MASTER Cohort. Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients. J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):312-8. doi: 10.1097/QAI.0000000000000585. PubMed PMID: 25723139.

98: Postorino MC, Prosperi M, **Quiros-Roldan E**, Maggiolo F, Di Giambenedetto S, Saracino A, Costarelli S, Lorenzotti S, Sighinolfi L, Di Pietro M, Torti C; MASTER Study Group. Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort. Clin Microbiol Infect. 2015 Apr;21(4):386.e1-9. doi: 10.1016/j.cmi.2014.10.022. Epub 2014 Nov 11. PubMed PMID: 25595708.

99: Fabbiani M, Di Giambenedetto S, **Quiros-Roldan E**, Latini A, Vullo V, Antinori A, Castagna A, Orofino G, Francisci D, Grilli E, Madeddu G, Grima P, Rusconi S, Del Pin B, Mondi A, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R. Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19808. doi: 10.7448/IAS.17.4.19808. eCollection 2014. PubMed PMID: 25397552; PubMed Central PMCID: PMC4225257.

100: Cingolani A, Zona S, Girardi E, Lepri AC, Monno L, **Quiros Roldan E**, Guaraldi

G, Antinori A, Monforte Ad, Marcotullio S; ICONA Foundation Study. Increased incidence of sexually transmitted diseases in the recent years: data from the ICONA cohort. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19653. doi: 10.7448/IAS.17.4.19653. eCollection 2014. PubMed PMID: 25394157; PubMed Central PMCID: PMC4224872.

101: d'Arminio Monforte A, Galli L, Lo Caputo S, Lichtner M, Pinnetti C, Bobbio N, Francisci D, Costantini A, Cingolani A, Castelli F, Girardi E, Castagna A; ICONA Foundation Study Group (**including Quiros-Roldan E**) . Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013. J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):258-67. doi: 10.1097/QAI.0000000000000297. PubMed PMID: 25314248.

102: Sorlini ML, Focà E, Motta D, Salvi A, Compostella S, Brianese N, Ferraresi A, Casari S, Romanelli G, Castelli F, **Quiros Roldan E**. Elderly women with human immunodeficiency virus infection: is there an effect of the virus on neuropsychological profile? J Am Geriatr Soc. 2014 Jan;62(1):194-6. PubMed PMID: 25180386.

103: Lichtner M, Cicconi P, Vita S, Cozzi-Lepri A, Galli M, Lo Caputo S, Saracino A, De Luca A, Moioli M, Maggiolo F, Marchetti G, Vullo V, d'Arminio Monforte A; ICONA Foundation Study (**including Quiros-Roldan E**). Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. J Infect Dis. 2015 Jan 15;211(2):178-86. doi: 10.1093/infdis/jiu417. Epub 2014 Jul 31. PubMed PMID: 25081936.

104: Porcelli T, Gotti D, Cristiano A, Maffezzoni F, Mazziotti G, Focà E, Castelli F, Giustina A, **Quiros-Roldan E**. Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection. Osteoporos Int. 2014 Sep;25(9):2263-9. doi: 10.1007/s00198-014-2760-z. Epub 2014 Jul 24. PubMed PMID: 25056799.

105: Rozera G, Abbate I, Giombini E, Castagna A, De Luca A, Ceccherini-Silberstein F, Cozzi Lepri A, Cassola G, Torti C, d'Arminio Monforte A, Ippolito G,

Capobianchi MR; ICONA Foundation Group (**including Quiros-Roldan E**). Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. J Antimicrob Chemother. 2014 Nov;69(11):3085-94. doi: 10.1093/jac/dku255. Epub 2014 Jul 10. PubMed PMID: 25015667.

106: Petoumenos K, Reiss P, Ryom L, Rickenbach M, Sabin CA, El-Sadr W, d'Arminio Monforte A, Phillips AN, De Wit S, Kirk O, Dabis F, Pradier C, Lundgren JD, Law MG; D:A:D study group (**including Quiros-Roldan E**). Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. HIV Med. 2014 Nov;15(10):595-603. doi: 10.1111/hiv.12162. Epub 2014 May 19. PubMed PMID: 24840675.

107: Gotti D, Raffetti E, Albini L, Sighinolfi L, Maggiolo F, Di Filippo E, Ladisa N, Angarano G, Lapadula G, Pan A, Esposti AD, Fabbiani M, Focà E, Scalzini A, Donato F, **Quiros-Roldan E**; Master Cohort Group. Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter study. PLoS One. 2014 Apr 23;9(4):e94768. doi: 10.1371/journal.pone.0094768. eCollection 2014. PubMed PMID: 24760049; PubMed Central PMCID: PMC3997420.

108: Kamara DA, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux CA, Mocroft A, Sabin C, Lundgren JD, Smith CJ; D:A:D study Group (**including Quiros-Roldan E**). Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. BMC Nephrol. 2014 Mar 25;15:51. doi: 10.1186/1471-2369-15-51. PubMed PMID: 24666792; PubMed Central PMCID: PMC3987148.

109: Serana F, Chiarini M, **Quiros-Roldan E**, Gotti D, Zanotti C, Sottini A, Bertoli D, Caimi L, Imberti L. Modulation of Regulatory T-Cell Subsets in Very Long-Term Treated Aviremic HIV(+) Patients and Untreated Viremic Patients. Open AIDS J. 2014 Feb 7;8:1-6. doi: 10.2174/1874613601408010001. eCollection 2014. PubMed PMID: 24627733; PubMed Central PMCID: PMC3952203.

110: Amadasi S, Odolini S, Foca E, Panzali A, Cerini C, Lonati L, Pezzoli MC, Nasta P, Casari S, Castelli F, **Quiros-Roldan E**. Evaluation of boosted and

unboosted atazanavir plasma concentration in HIV infected patients. Curr HIV Res. 2013 Dec;11(8):642-6. PubMed PMID: 24517189.

111: Meini G, Rossetti B, Bianco C, Ceccherini-Silberstein F, Di Giambenedetto S, Sighinolfi L, Monno L, Castagna A, Rozera G, D'Arminio Monforte A, Zazzi M, De Luca A; ICONA Foundation Group (**including Quiros-Roldan E**). Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. J Antimicrob Chemother. 2014 Mar;69(3):735-41. doi: 10.1093/jac/dkt426. Epub 2013 Oct 23. PubMed PMID: 24155059; PubMed Central PMCID: PMC3954119.

112: Raffi F, Jaeger H, **Quiros-Roldan E**, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S; extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013 Nov;13(11):927-35. doi: 10.1016/S1473-3099(13)70257-3. Epub 2013 Sep 25. PubMed PMID: 24074642.

113: d'Arminio Monforte A, Gianotti N, Cozzi-Lepri A, Pinnetti C, Andreoni M, di Perri G, Galli M, Poli A, Costantini A, Orofino G, Maggiolo F, Mazzarello G, Celesia BM, Luciani F, Lazzarin A, Sighinolfi L, Rizzardini G, Bonfanti P, Perno CF, Antinori A; ICONA Foundation Cohort (**including Quiros-Roldan E**). Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤ 50 copies/ml in an observational setting. Antivir Ther. 2014;19(3):319-24. doi: 10.3851/IMP2687. Epub 2013 Sep 13. PubMed PMID: 24036891.

114: Castagna A, Galli L, Gianotti N, Torti C, Antinori A, Maserati R, d'Arminio Monforte A, **Quiros-Roldan E**, Salpietro S, Lazzarin A. Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens. New Microbiol. 2013 Jul;36(3):239-49. Epub 2013 Jun 30. PubMed PMID: 23912865.

115: Calabresi A, Ferraresi A, Limina RM, Donato F, Scarcella C, Vassallo F, Paraninfo G, Torti C, Castelli F, **Quiros-Roldan E**. [A population-based database

to study malignancies in HIV-infected patients in the Local Health Unit of Brescia (Northern Italy), period 1999-2009]. Epidemiol Prev. 2013 Mar-Jun;37(2-3):153-60. Italian. PubMed PMID: 23851245.

116: Gotti D, Danesi M, Calabresi A, Ferraresi A, Albini L, Donato F, Castelli F, Scalzini A, **Quiros-Roldan E**; Brescia HIV Cancer Study Group. Clinical characteristics, incidence, and risk factors of HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy. AIDS Patient Care STDS. 2013 May;27(5):259-65. doi: 10.1089/apc.2012.0424. Epub 2013 Apr 21. PubMed PMID: 23600703.

117: Albini L, Calabresi A, Gotti D, Ferraresi A, Festa A, Donato F, Magoni M, Castelli F, **Quiros-Roldan E**. Burden of non-AIDS-defining and non-virus-related cancers among HIV-infected patients in the combined antiretroviral therapy era. AIDS Res Hum Retroviruses. 2013 Aug;29(8):1097-104. doi: 10.1089/AID.2012.0321. Epub 2013 May 9. PubMed PMID: 23581483.

118: Calabresi A, Ferraresi A, Festa A, Scarcella C, Donato F, Vassallo F, Limina R, Castelli F, **Quiros-Roldan E**; Brescia HIV Cancer Study Group. Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009. HIV Med. 2013 Sep;14(8):481-90. doi: 10.1111/hiv.12034. Epub 2013 Apr 7. PubMed PMID: 23560682.

119: De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnernborg A, Codoñer FM, Van Laethem K, Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe D, Prosperi MC, Di Giambenedetto S; SEHERE collaboration in Chain (**including Quiros-Roldan E**). Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 2013 Apr 15;207(8):1216-20. doi: 10.1093/infdis/jit017. Epub 2013 Jan 11. PubMed PMID: 23315324.

120: Calabresi A, Castelnovo F, Ferraresi A, **Quiros-Roldan E**. Male breast cancer in an HIV-infected patient: a case report. Infez Med. 2012 Dec;20(4):284-7. PubMed PMID: 23299069.

121: Efsen AM, Panteleev AM, Grint D, Podlekareva DN, Vassilenko A, Rakhmanova A, Zeltina I, Losso MH, Miller RF, Girardi E, Caylá J, Post FA, Miro JM, Bruyand M, Furrer H, Obel N, Lundgren JD, Mocroft A, Kirk O; HIV/TB Study Group (**including Quiros-Roldan E**). TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortality. Biomed Res Int. 2013;2013:373601. doi: 10.1155/2013/373601. Epub 2013 Dec 31. PubMed PMID: 24699884; PubMed Central PMCID: PMC3930027.

121: Gotti D, Cesana BM, Albini L, Calabresi A, Izzo I, Focà E, Motta D, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Brianese N, **Quiros-Roldan E**, Guaraldi G, Torti C. Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir. HIV Clin Trials. 2012 Sep-Oct;13(5):245-55. doi: 10.1310/hct1305-245. PubMed PMID: 23134625.

122: Ferraresi A, Calabresi A, Castelli F, Vavassori A, Castelnuovo F, Scalzini A, Torti C, **Quiros-Roldan E**. Lung cancer in HIV-infected patients: the experience in Brescia from 1999 to 2009. Int J STD AIDS. 2012 Oct;23(10):753-5. doi: 10.1258/ijsa.2012.012042. PubMed PMID: 23104752.

123: Calabresi A, Ferraresi A, Vavassori A, Castelli F, **Quiros-Roldan E**. Breast cancer among human immunodeficiency virus (HIV)-infected patients: the experience in Brescia, Northern Italy. Braz J Infect Dis. 2012 Jul-Aug;16(4):396-7. doi: 10.1016/j.bjid.2012.06.001. PubMed PMID: 22846133.

124: Focà E, Motta D, Pollara C, Brianese N, Gotti D, Albini L, **Quiros-Roldan E**, Torti C, Manca N. Impact of detectable human cytomegalovirus DNAemia on viro-immunological effectiveness of HAART in HIV-infected patients naive to antiretroviral therapy. New Microbiol. 2012 Apr;35(2):227-31. Epub 2012 Mar 31. PubMed PMID: 22707137.

125: **Quiros-Roldan E**, Serana F, Chiarini M, Zanotti C, Sottini A, Gotti D, Torti C, Caimi L, Imberti L. Effects of combined antiretroviral therapy on B- and

T-cell release from production sites in long-term treated HIV-1+ patients. J

Transl Med. 2012 May 16;10:94. doi: 10.1186/1479-5876-10-94. PubMed PMID: 22591651; PubMed Central PMCID: PMC3481359.

126: Colafigli M, Torti C, Trecarichi EM, Albini L, Rosi A, Micheli V, Manca N, Penco G, Bruzzone B, Punzi G, Corsi P, Parruti G, Bagnarelli P, Monno L, Gonnelli A, Cauda R, Di Giambenedetto S; ARCA, UCSC and Brescia HIV resistance study Groups (**including Quiros-Roldan E**). Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. Clin Microbiol Infect. 2012 Aug;18(8):E299-304. doi: 10.1111/j.1469-0691.2012.03847.x. Epub 2012 Apr 27. PubMed PMID: 22536753.

127: Focà E, Motta D, Borderi M, Gotti D, Albini L, Calabresi A, Izzo I, Bellagamba R, Narciso P, Sighinolfi L, Clò A, Gibellini D, **Quiros-Roldan E**, Brianese N, Cesana BM, Re MC, Torti C. Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. BMC Infect Dis. 2012 Feb 14;12:38. doi: 10.1186/1471-2334-12-38. PubMed PMID: 22333484; PubMed Central PMCID: PMC3296645.

128: Ammassari A, Trotta MP, Shalev N, Tettoni MC, Maschi S, Di Sora F, Orofino G, d'Ettorre G, Bai F, Celesia MB, **Quiros Roldan E**, Maserati R, Sterrantino G, Tommasi C, Boumis E, Iardino MR, Antinori A. Timed short messaging service improves adherence and virological outcomes in HIV-1-infected patients with suboptimal adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):e113-5. doi: 10.1097/QAI.0b013e3182359d2a. Erratum in: J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):e8. Tommassi, Chiara [corrected to Tommasi, Chiara]. PubMed PMID: 22033235.

129: d'Arminio Monforte A, Cozzi-Lepri A, Girardi E, Castagna A, Mussini C, Di Giambenedetto S, Galli M, Cassola G, Vullo V, **Quiros-Roldan E**, Lo Caputo S, Antinori A; Icona Foundation Study Group. Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. Antivir Ther. 2011;16(7):1103-12. doi: 10.3851/IMP1883. PubMed PMID: 22024526.

130: Albini L, Cesana BM, Motta D, Focà E, Gotti D, Calabresi A, Izzo I,

Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, **Quiros-Roldan E**, Manili L, Guaraldi G, Lapadula G, Torti C. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. *J Acquir Immune Defic Syndr*. 2012 Jan 1;59(1):18-30. doi: 10.1097/QAI.0b013e31823a6124. PubMed PMID: 21992924.

131: Torti C, Prosperi M, Motta D, Digiambenedetto S, Maggiolo F, Paraninfo G, Ripamonti D, Cologni G, Fabbiani M, Caputo SL, Sighinolfi L, Ladisa N, El-Hamad I, **Quiros-Roldan E**, Frank I. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. *Clin Microbiol Infect*. 2012 May;18(5):449-58. doi: 10.1111/j.1469-0691.2011.03650.x. Epub 2011 Sep 15. PubMed PMID: 21919996.

132: Pavie J, Porcher R, Torti C, Medrano J, Castagna A, Valin N, Rusconi S, Ammassari A, Ghosn J, Delaugerre C, Molina JM; NEAT Unboosted Atazanavir Cohort Study Group (**including Quiros-Roldan E**). Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. *J Antimicrob Chemother*. 2011 Oct;66(10):2372-8. doi: 10.1093/jac/dkr316. Epub 2011 Aug 5. PubMed PMID: 21821627.

133: Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sönnernborg A, Kaiser R, Codoñer FM, Van Laethem K, Bansi L, van de Vijver DA, Geretti AM, De Luca A; SEHERE consortium (**including Quiros-Roldan E**). Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. *J Antimicrob Chemother*. 2011 Aug;66(8):1886-96. doi: 10.1093/jac/dkr171. Epub 2011 May 30. PubMed PMID: 21624929.

134: Mendeni M, Focà E, Gotti D, Ladisa N, Angarano G, Albini L, Castelnovo F, Carosi G, **Quiros-Roldan E**, Torti C. Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in

a cohort of HIV-infected patients without hepatitis C and B infection. Clin Infect Dis. 2011 May;52(9):1164-73. doi: 10.1093/cid/cir071. PubMed PMID: 21467023.

135: Izzo I, Forleo MA, Casari S, **Quiros-Roldan E**, Magoni M, Carosi G, Torti C. Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy). BMC Public Health. 2011 Feb 21;11:124. doi: 10.1186/1471-2458-11-124. PubMed PMID: 21338498; PubMed Central PMCID: PMC3058020.

136: Torti C, d'Arminio-Monforte A, Pozniak AL, Lapadula G, Cologni G, Antinori A, De Luca A, Mussini C, Castagna A, Cicconi P, Minoli L, Costantini A, Carosi G, Liang H, Cesana BM; MASTER (**including Quiros-Roldan E**), Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. BMC Infect Dis. 2011 Jan 25;11:23. doi: 10.1186/1471-2334-11-23. PubMed PMID: 21266068; PubMed Central PMCID: PMC3038912.

137: Gotti D, Focà E, Albini L, Mendeni M, Vavassori A, **Quiros Roldan E**, Torti C. Cryptogenic liver diseases: sailing by sight from HIV co-infection with hepatitis viruses to HIV mono-infection through the Pillars of Hercules. Curr HIV Res. 2011 Jan;9(1):61-9. Review. PubMed PMID: 21198429.

138: **Quiros-Roldan E**, Amadasi S, Paraninfo G, Izzo I, Allegri R, Motta D, Gatti F, Cristini G, Carosi G, Mendeni M, Torti C. The impact of gender and anchor drugs on TDF renal toxicity. J Acquir Immune Defic Syndr. 2010 Oct;55(2):e11-2. doi: 10.1097/QAI.0b013e3181ef7930. PubMed PMID: 20859083.

139: Magoni M, Scarcella C, Vassallo F, Lonati F, Carosi G, Castelnovo F, **Quiros-Roldan E**, Albini L, Gennaro N, Bishai D, Tramarin A, Torti C. The evolving burden of HIV infection compared with other chronic diseases in northern Italy. HIV Med. 2011 Mar;12(3):129-37. doi: 10.1111/j.1468-1293.2010.00861.x. PubMed PMID: 20666848.

140: Frentz D, Boucher CA, Assel M, De Luca A, Fabbiani M, Incardona F, Libin P, Manca N, Müller V, O Nualláin B, Paredes R, Prosperi M, **Quiros-Roldan E**, Ruiz L, Sloot PM, Torti C, Vandamme AM, Van Laethem K, Zazzi M, van de Vijver DA. Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One. 2010 Jul 9;5(7):e11505. doi: 10.1371/journal.pone.0011505. PubMed PMID: 20634893; PubMed Central PMCID: PMC2901338.

141: Seminari E, Tinelli C, Ravasi G, Ripamonti D, Ladisa N, Marino N, Sighinolfi L, Mondello P, Migliorino M, Carosi G, Maserati R; MASTER Cohort (**including Quiros-Roldan E**) . Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3. Curr HIV Res. 2010 Apr;8(3):186-93. PubMed PMID: 20163342.

142: Torti C, Lapadula G, Izzo I, Brindicci G, Labbate G, **Quiros-Roldan E**, Diallo I, Gargiulo F, Castelnuovo F, Calabresi A, Carosi G, Manca N, Monno L. Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implications. Epidemiol Infect. 2010 Sep;138(9):1298-307. doi: 10.1017/S0950268810000166. Epub 2010 Jan 29. PubMed PMID: 20109261.

143: Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Paraninfo G, Ladisa N, Zazzi M, Trezzi M, Cicconi P, Corsi P, Nasta P, Cauda R, De Luca A; UCSC cohort; MASTER cohort(**including Quiros-Roldan E**) ; ARCA cohort. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study. Infection. 2009 Oct;37(5):438-44. doi: 10.1007/s15010-009-8237-x. Epub 2009 Aug 7. PubMed PMID: 19669091.

144: Müller V, Maggiolo F, Suter F, Ladisa N, De Luca A, Antinori A, Sighinolfi L, **Quiros-Roldan E**, Carosi G, Torti C. Increasing clinical virulence in two decades of the Italian HIV epidemic. PLoS Pathog. 2009 May;5(5):e1000454. doi: 10.1371/journal.ppat.1000454. Epub 2009 May 29. PubMed PMID: 19478880; PubMed Central PMCID: PMC2682199.

145: Lapadula G, Calabresi A, Castelnovo F, Costarelli S, **Quiros-Roldan E**, Paraninfo G, Ceresoli F, Gargiulo F, Manca N, Carosi G, Torti C. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. *Antivir Ther.* 2008;13(4):601-5. PubMed PMID: 18672539.

146: Costarelli S, Torti C, Rodella A, Baldanti F, Paolucci S, Lapadula G, Manca N, **Quiros-Roldan E**, Izzo I, Carosi G. Screening and Management of HIV-2-Infected Individuals in Northern Italy. *AIDS Patient Care STDS.* 2008 Jun;22(6):489-94. doi: 10.1089/apc.2007.0149. PubMed PMID: 18582190.

147: **Quiros-Roldan E**, Calabresi A, Lapadula G, Tirelli V, Costarelli S, Cologni G, Zaltron S, Puoti M, Carosi G, Torti C. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfectd by HIV. *Antivir Ther.* 2008;13(3):341-8. PubMed PMID: 18572746.

148: Sighinolfi L, Torti C, Zeni C, Ghinelli F, Suter F, Maggiolo F, Antinori A, Antonucci G, Castelnovo F, Ladisa N, Migliorino M, Novati S, De Luca A, Lo Caputo S, Paraninfo G, Tinelli C, Carosi G; Italian MASTER Database Cohort (**including Quiros-Roldan E**). Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study. *Infection.* 2008 Jun;36(3):244-9. doi: 10.1007/s15010-007-7227-0. Epub 2008 May 3. PubMed PMID: 18454340.

149: Lapadula G, Costarelli S, **Quiros-Roldan E**, Calabresi A, Izzo I, Carosi G, Torti C. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naïve HIV-infected patients. *Clin Infect Dis.* 2008 Apr 1;46(7):1127-9. doi: 10.1086/529394. PubMed PMID: 18444839.

150: Lapadula G, Izzo I, Gargiulo F, Paraninfo G, Castelnovo F, **Quiros-Roldan E**, Cologni G, Ceresoli F, Manca N, Carosi G, Torti C. Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral

therapy: a single center analysis. J Med Virol. 2008 May;80(5):747-53. doi: 10.1002/jmv.21139. PubMed PMID: 18360912.

151: Pan A, Testa S, **Quiros Roldan E**, Tinelli C, Bodini U, Cadeo B, Carnevale G, Martinelli I, Maserati R, Morstabilini P, Seminari E, Signorini L, Carosi G. Haemostatic activation in HIV infected patients treated with different antiretroviral regimens. Curr HIV Res. 2008 Jan;6(1):70-6. PubMed PMID: 18288978.

152: Torti C, **Quiros-Roldan ME**, Cologni G, Nichelatti M, Ceresoli F, Pinti M, Nasi M, Cossarizza A, Lapadula G, Costarelli S, Manca N, Gargiulo F, Magoni M, Carosi G. Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals. Curr HIV Res. 2008 Jan;6(1):43-8. PubMed PMID: 18288974.

153: Torti C, Costarelli S, De Silvestri A, **Quiros-Roldan E**, Lapadula G, Cologni G, Paraninfo G, Castelnuovo F, Puoti M, Carosi G; BHCC Study Group. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. Drug Saf. 2007;30(12):1161-9. PubMed PMID: 18035868.

154: Costarelli S, Torti C, Gatta LB, Tinelli C, Lapadula G, **Quiros-Roldan E**, Izzo I, Castelnuovo F, Biasiotto G, Arosio P, Carosi G. No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):255-6. PubMed PMID: 17895769.

155: Torti C, Lapadula G, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Pietro MD, Migliorino G, **Quiros-Roldan E**, Ladisa N, Sighinolfi L, Gatti F, Carosi G; Italian MASTER Cohort. Predictors of AIDS-defining events among advanced naïve patients after HAART. HIV Clin Trials. 2007 May-Jun;8(3):112-20. PubMed PMID: 17621458.

156: Carosi G, **Quiros-Roldan E**, Torti C, Antinori A, Bevilacqua M, Bonadonna RC, Bonfanti P, Castagna A, Cauda R, d'Arminio-Monforte A, Di Gregorio P, Di Perri G,

Esposito R, Fatuzzo F, Gervasoni C, Giannattasio C, Guaraldi G, Lazzarin A, Lo Caputo S, Maggi P, Mazzotta F, Moroni M, Prestileo T, Ranieri R, Rizzardini G, Russo R, Galli M; Members of the Italian Cardiovascular Risk Guidelines Working Group. First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006). *Infection*. 2007 Jun;35(3):134-42. PubMed PMID: 17565453.

157: **Quiros-Roldan E**, Tirelli V, Torti C, Sosta E, Tosoni C, Damiolini E, Carosi G. Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide. *AIDS*. 2007 Jun 19;21(10):1388-9. PubMed PMID: 17545726.

158: **Quiros-Roldan E**, Torti C, Lapadula G, Ladisa N, Micheli V, Patroni A, Cusato M, Pierotti P, Tirelli V, Uccelli MC, Di Giambenedetto S, Castelnovo F, Gargiulo F, Manca N, Carosi G; RADAR-Master Study Group. Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy. *AIDS Patient Care STDS*. 2007 Feb;21(2):92-9. PubMed PMID: 17328658.

159: Maggiolo F, Ripamonti D, Torti C, Arici C, Antinori A, **Quiros-Roldan E**, Minoli L, Sighinolfi L, Nasta P, Suter F; MASTER Data Base Cohort. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens. *Antivir Ther*. 2006;11(7):923-9. PubMed PMID: 17302255.

160: Torti C, Lapadula G, Uccelli MC, **Quiros-Roldan E**, Regazzi M, Ladisa N, Micheli V, Orani A, Patroni A, Caputo SL, Tirelli V, Di Giambenedetto S, Cologni G, Costarelli S, Gargiulo F, Manca N, Carosi G; RADAR Study Group of MASTER Cohort. Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. *Int J Antimicrob Agents*. 2007 Feb;29(2):185-90. Epub 2006 Oct 2. PubMed PMID: 17011754.

161: Uccelli MC, Torti C, Lapadula G, Labate L, Cologni G, Tirelli V, Moretti F,

Costarelli S, **Quiros-Roldan E**, Carosi G. Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART. *Ann Nutr Metab.* 2006;50(3):247-52. Epub 2006 Feb 23. PubMed PMID: 16508252.

162: Pan A, Dolcetti L, Barosi C, Catenazzi P, Ceruti T, Ferrari L, Magri S, **Quiros Roldan E**, Soavi L, Carnevale G. An outbreak of *Serratia marcescens* bloodstream infections associated with misuse of drug vials in a surgical ward. *Infect Control Hosp Epidemiol.* 2006 Jan;27(1):79-82. Epub 2006 Jan 6. PubMed PMID: 16418994.

163: Torti C, Uccelli MC, **Quiros-Roldan E**, Gargiulo F, Tirelli V, Lapadula G, Regazzi M, Pierotti P, Tinelli C, De Luca A, Patroni A, Manca N, Carosi G. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors. *J Clin Virol.* 2006 Apr;35(4):414-9. Epub 2005 Nov 8. PubMed PMID: 16280255.

164: Torti C, **Quiros-Roldan E**, Regazzi M, Antinori A, Patroni A, Villani P, Tirelli V, Cologni G, Zinzi D, Lo Caputo S, Perini P, Carosi G; KARINA-SISTHER Collaboration Group of the MASTER Cohort. Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. *Antivir Ther.* 2005;10(4):505-13. PubMed PMID: 16038476.

165: Torti C, Lapadula G, Casari S, Puoti M, Nelson M, **Quiros-Roldan E**, Bella D, Pastore G, Ladisa N, Minoli L, Sotgiu G, Mazzotta F, Lo Caputo S, Di Perri G, Filice G, Tinelli C, Carosi G; EPOKA-MASTER Study Group. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. *BMC Infect Dis.* 2005 Jul 14;5:58. PubMed PMID: 16018804; PubMed Central PMCID: PMC1188059.

166: **Quiros-Roldan E**, Moretti F, Torti C, Tirelli V, Stellini R, Pirovano S,

Carosi G, Imberti L. Potential role of SEN virus on liver enzyme abnormalities in patients positive for hepatitis C virus with or without HIV infection. *Eur J Clin Microbiol Infect Dis*. 2005 Jun;24(6):436-7. PubMed PMID: 15926060.

167: Torti C, **Quiros-Roldan E**, Regazzi M, De Luca A, Mazzotta F, Antinori A, Ladisa N, Micheli V, Orani A, Patroni A, Villani P, Lo Caputo S, Moretti F, Di Giambenedetto S, Castelnuevo F, Maggi P, Tinelli C, Carosi G; RADAR-MASTER Study Group. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. *Clin Infect Dis*. 2005 Jun 15;40(12):1828-36. Epub 2005 May 12. PubMed PMID: 15909273.

168: **Quiros-Roldán E**, Torti C, Carosi G. [Usefulness of pharmacokinetics in the management of antiretroviral therapy]. *Med Clin (Barc)*. 2005 May 14;124(18):695-6. Spanish. PubMed PMID: 15899165.

169: Pan A, Carnevale G, Catenazzi P, Colombini P, Crema L, Dolcetti L, Ferrari L, Mondello P, Signorini L, Tinelli C, **Quiros Roldan E**, Carosi G. Trends in methicillin-resistant *Staphylococcus aureus* (MRSA) bloodstream infections: effect of the MRSA "search and isolate" strategy in a hospital in Italy with hyperendemic MRSA. *Infect Control Hosp Epidemiol*. 2005 Feb;26(2):127-33. PubMed PMID: 15756881.

170: **Quiros-Roldan E**, Torti C, Tinelli C, Moretti F, Zanini B, Tirelli V, Pan A, Casari S, Carosi G. Risk factors for myocardial infarction in HIV-positive patients. *Int J STD AIDS*. 2005 Jan;16(1):14-8. PubMed PMID: 15705266.

171: **Quiros-Roldan E**, Moretti F, Torti C, Tirelli V, Casari S, Carosi G. HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir-containing regimens. *J Clin Lab Anal*. 2005;19(1):26-9. PubMed PMID: 15645464.

172: Torti C, **Quiros-Roldan E**, Tirelli V, Regazzi-Bonora M, Moretti F, Pierotti P, Orani A, Maggi P, Cargnel A, Patroni A, De Luca A, Carosi G; RADAR Study Group

of the Master Cohort. Lopinavir plasma levels in salvage regimes by a population of highly active antiretroviral therapy-treated HIV-1-positive patients. *AIDS Patient Care STDS*. 2004 Nov;18(11):629-34. PubMed PMID: 15633260.

173: **Quiros-Roldan E**, Torti C, Pirovano S, Moretti F, Casari S, Carosi G, Soriano V, Imberti L. Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target? *Intervirology*. 2004;47(6):350-4. PubMed PMID: 15564747.

174: Torti C, Bono L, Gargiulo F, Uccelli MC, **Quiros-Roldan E**, Patroni A, Paraninfo G, Tirelli V, Manca N, De Francesco MA, Perandin F, Carosi G. Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive patients naïve for anti-retrovirals. *Clin Microbiol Infect*. 2004 Sep;10(9):826-30. PubMed PMID: 15355414.

175: Torti C, Cologni G, Uccelli MC, **Quiros-Roldan E**, Imberti L, Airó P, Pirovano S, Patroni A, Tirelli V, Carosi G. Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART). *Viral Immunol*. 2004;17(2):279-86. PubMed PMID: 15279705.

176: Torti C, **Quiros-Roldan E**, Monno L, Patroni A, Saracino A, Angarano G, Tinelli C, Lo Caputo S, Tirelli V, Mazzotta F, Carosi G; MASTER Cohort GenPheRex Study Group; MASTER Cohort PhenGen Study Group. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. *J Med Virol*. 2004 Sep;74(1):29-33. PubMed PMID: 15258965.

177: Torti C, **Quiros-Roldan E**, Monno L, Patroni A, Saracino A, Angarano G, Tinelli C, Mazzotta F, Lo Caputo S, Pierotti P, Carosi G; GenPheRex PhenGen Study Groups of the MASTER Cohort. HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations. *J Acquir Immune Defic Syndr*. 2004 Aug 15;36(5):1104-7. PubMed PMID: 15247566.

178: **Quiros-Roldán E**, Torti C, Carosi G. [The novel non-A, non-E hepatitis viruses and their pathogenic effect]. Med Clin (Barc). 2004 Apr 17;122(14):552-4. Review. Spanish. PubMed PMID: 15117650.

179: Torti C, **Quiros-Roldán E**, Regazzi-Bonora M, De Luca A, Lo Caputo S, Di Giambenedetto S, Patroni A, Villani P, Micheli V, Carosi G; Resistance and Dosage Adapted Regimens Study Group of the MASTER Cohort. Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):324-6. PubMed PMID: 15076251.

180: Torti C, Barnes E, **Quiros-Roldán E**, Puoti M, Carosi G, Klenerman P. Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection. Antivir Ther. 2004 Feb;9(1):139-42. PubMed PMID: 15040546.

181: **Quiros-Roldán E**, Moretti F, Torti C, Casari S, Prestini K, Carosi G. HIV-associated asymmetric lipodystrophy syndrome. Rev Clin Esp. 2004 Mar;204(3):177. PubMed PMID: 15025990.

182: **Quiros-Roldán E**, Torti C, Imberti L, Casari S, Soriano V, Moretti F, Pirovano S, Carosi G. SENV infection in HIV-positive patients: prevalence, subtype characterization, and impact on HIV disease progression. AIDS Res Hum Retroviruses. 2003 Dec;19(12):1079-82. PubMed PMID: 14709243.

183: Tomasoni LR, Patroni A, Torti C, Paraninfo G, Gargiulo F, **Quiros-Roldán E**, Uccelli MC, Airò P, Tinelli C, Carosi G, Castelli F; Brescia-MASTER Study Group. Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch. HIV Clin Trials. 2003 Sep-Oct;4(5):311-23. PubMed PMID: 14583847.

184: Scudeller L, Torti C, **Quiros-Roldán E**, Patroni A, Lo Caputo S, Moretti F, Mazzotta F, Donati E, Vivarelli A, Carosi G; GenPheRex Group of the MASTER Cohort. HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations. J Antimicrob Chemother. 2003 Nov;52(5):776-81. Epub 2003 Oct 16.

PubMed PMID: 14563897.

185: Torti C, Casari S, Palvarini L, **Quiros-Roldan E**, Moretti F, Leone L, Patroni A, Castelli F, Ripamonti D, Tramarin A, Carosi G. Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting. Health Policy. 2003 Sep;65(3):261-7. PubMed PMID: 12941493.

186: Torti C, **Quiros-Roldan E**, Scudeller L, Lo Caputo S, Tomasoni L, Castelli F, Poggio A, Delle Foglie P, Chirianni A, Sighinolfi L, Mazzotta F, Carosi G; GenPheRex Group of the Ma.S.Te.R. Cohort. Characterization of viro-immunological responses in a closely followed cohort of heavily pretreated patients: evidence from the GenPheRex Study. HIV Med. 2003 Jul;4(3):263-70. PubMed PMID: 12859326.

187: Torti C, **Quiros-Roldan E**, Keulen W, Scudeller L, Lo Caputo S, Boucher C, Castelli F, Mazzotta F, Pierotti P, Been-Tiktak AM, Buccoliero G, De Gennaro M, Carosi G, Tinelli C; GenPherex Study Group of the MaSTeR Cohort. Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients. J Infect Dis. 2003 Jul 15;188(2):194-201. Epub 2003 Jul 1. PubMed PMID: 12854073.

188: **Quiros-Roldan E**, Moretti F, Torti C, Casari S, Castelli F, Beltrame A, Carosi G. HIV/HTLV co-infection: frequency and epidemiological characteristics among patients admitted to an Italian hospital. Infection. 2003 Jun;31(3):172-3. PubMed PMID: 12789475.

189: Torti C, Moretti F, Uccelli MC, Tirelli V, **Quiros-Roldan E**, Gargiulo F, Carosi G. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case. Med Sci Monit. 2003 Apr;9(4):CS16-9. PubMed PMID: 12709675.

190: **Quiros-Roldan E**, Torti C, Casari S, Moretti F, Puoti M, Carosi G, Bercich L. Polymorphic immune restoration syndrome after effective HAART. Sex Transm Infect. 2003 Apr;79(2):171-2. PubMed PMID: 12690150; PubMed Central PMCID: PMC1744636.

191: Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G, Maserati R, Gianotti N, Ladisa N, **Quiros-Roldan E**, Rinehart AR, Carosi G; Genotipo-Fenotipo di Resistenza (GenPheRex) Group of the Italian Management Standardizzato di Terapia Antiretrovirale (MASTER) Cohort. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):268-80. PubMed PMID: 12626886.

192: Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, Spinetti A, Putzolu V, Casari S, Tomasoni L, **Quiros-Roldan E**, Favret M, Berchich L, Grigolato P, Callea F, Carosi G; HIV-HCV Co-Infection Study Group. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):259-67. PubMed PMID: 12626885.

193: Patroni A, Torti C, Tomasoni L, **Quiros Roldan E**, Bertelli D, Puoti M, Cadeo GP, Sleiman I, Tinelli C, Carosi G, Castelli F. Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study. HIV Clin Trials. 2002 Nov-Dec;3(6):451-61. PubMed PMID: 12501128.

194: Uccelli MC, Torti C, **Quiros-Roldan E**, Tinelli C, Patroni A, Castelli F, Carosi G, Airò P. Bcl-2 expression is moderately correlated with long-term variability of CD4 T-cell increase under successful highly active antiretroviral therapy. AIDS. 2003 Jan 3;17(1):141-3. PubMed PMID: 12478088.

195: **Quirós-Roldán E**, Pan A, Moretti F, Casari S, Carosi G. [Peripheral lipodystrophy]. Rev Clin Esp. 2002 Nov;202(11):622. Spanish. PubMed PMID: 12392654.

196: **Quirós Roldán E**, Maroto Vela MC. [Some considerations regarding resistance

mechanism to antiretrovirals in HIV infection]. Rev Clin Esp. 2002 Sep;202(9):469-71. Spanish. PubMed PMID: 12236935.

197: Puoti M, Zanini B, Bruno R, Airoidi M, Rossi S, **Quiros Roldan E**, El Hamad I, Moretti F, Castelli F, Sacchi P, Filice G, Carosi G. Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV. HIV Clin Trials. 2002 Jul-Aug;3(4):324-32. Review. PubMed PMID: 12187507.

198: Moretti F, **Quiros-Roldan E**, Casari S, Viale P, Chiodera A, Carosi G. Rhodococcus equi: pulmonary cavitation lesion in patient infected with HIV cured by levofloxacin and rifampicin. AIDS. 2002 Jul 5;16(10):1440-2. PubMed PMID: 12131231.

199: **Quiros-Roldan E**, Maroto MC, Torti C, Moretti F, Casari S, Pan A, Carosi G. No evidence of beneficial effect of GB virus type C infection on the course of HIV infection. AIDS. 2002 Jul 5;16(10):1430-1. PubMed PMID: 12131224.

200: Moretti F, Uberti-Foppa C, **Quiros-Roldan E**, Fanti L, Lillo F, Lazzarin A. Oesophagobronchial fistula caused by varicella zoster virus in a patient with AIDS: a unique case. J Clin Pathol. 2002 May;55(5):397-8. PubMed PMID: 11986352; PubMed Central PMCID: PMC1769657.

201: **Quiros-Roldan E**, Airoidi M, Moretti F, Fausti C, Pan A, Casari S, Torti C, Castelli F, Carosi G. Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy. J Clin Lab Anal. 2002;16(2):76-8. PubMed PMID: 11948795.

202: Torti C, Patroni A, Tinelli C, Sleiman I, **Quiros-Roldan E**, Puoti M, Castelli F. Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):315-7. PubMed PMID: 11873084.

203: **Quirós-Roldán E**, Torti C, Pan A, Carosi G. [New strategies and new drugs in

the salvage therapy for HIV infection]. Med Clin (Barc). 2002 Feb 23;118(6):222-4. Review. Spanish. PubMed PMID: 11864546.

204: **Quiros-Roldan E**, Castelli F, Pan A, Chiodera S, Casari S, Airoidi M, Carosi G. Evidence of HIV-2 infection in northern Italy. Infection. 2001 Dec;29(6):362-3. PubMed PMID: 11787844.

205: **Quiros-Roldan E**, Bertelli D, Signorini S, Airoidi M, Torti C, Moretti F, Carosi G. HIV-1 multi-dideoxynucleoside resistance mutation (Q151M): prevalence, associated resistance mutations and response to antiretroviral salvage treatment. Microbios. 2001;106(414):137-45. PubMed PMID: 11506064.

206: Puoti M, Cadeo GP, Putzolu V, Forleo MA, Barni MC, Cristini G, Rossi S, Spinetti A, Zaltron S, Zanini B, **Quiros-Roldan E**, Paraninfo G, Gargiulo F, Carosi G. Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone. Dig Liver Dis. 2001 Mar;33(2):163-72. PubMed PMID: 11346146.

207: **Quiros-Roldan E**, Moretti F, Airoidi M, Fausti C, Chiodera A, Castelli F, Carosi G. Long-term benefit of genotypic-guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multiexperienced patients. J Clin Lab Anal. 2001;15(3):127-30. PubMed PMID: 11344527.

208: **Quiros-Roldan E**, Signorini S, Castelli F, Torti C, Patroni A, Airoidi M, Carosi G. Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy. J Clin Lab Anal. 2001;15(1):43-6. PubMed PMID: 11170234.

209: **Quiros-Roldan E**, Piédrola G, Maroto MC. Anti-hepatitic C virus antibodies hidden in circulating antibody/antigen aggregates in HCV-RNA positive patients. Microbios. 2000;103(404):59-64. PubMed PMID: 11034447.

210: Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, **Quiros-Roldan E**, Zanini B, Casari S, Carosi G. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):211-7.

PubMed PMID: 10969344.

211: Puoti M, Gargiulo F, **Quiros Roldan E**, Chiodera A, Palvarini L, Spinetti A, Zaltron S, Putzolu V, Zanini B, Favilli F, Turano A, Carosi G. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment. J Infect Dis. 2000 Jun;181(6):2033-6. Epub 2000 May 31. PubMed PMID: 10837187.

212: Magalini A, Puoti M, Putzolu V, **Quiros-Roldan E**, Forleo MA, Rossi S, Zaltron S, Spinetti A, Zanini B, Zonaro A, Solfrini R, Carosi G. Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month. J Clin Lab Anal. 2000;14(3):120-4. PubMed PMID: 10797610.

213: Carosi G, Torti C, Palvarini L, **Quiros Roldan E**. HIV-1 pharmacoresistance: clinical and therapeutic implications. J Biol Regul Homeost Agents. 1999 Jul-Sep;13(3):163-71. Review. PubMed PMID: 10560750.

214: Gran B, Gestri D, Sottini A, **Quiròs Roldàn E**, Bettinardi A, Signorini S, Primi D, Ballerini C, Taiuti R, Amaducci L, Massacesi L. Detection of skewed T-cell receptor V-beta gene usage in the peripheral blood of patients with multiple sclerosis. J Neuroimmunol. 1998 May 1;85(1):22-32. PubMed PMID: 9626994.

215: **Quiròs-Roldán E**, Sottini A, Signoniri S, Primi D, Imberti L. [T-cell receptor repertoire in a CD4+ CD57+ population]. Sangre (Barc). 1997 Oct;42(5):399-400. Spanish. PubMed PMID: 9424741.

216: Bettinardi A, Imberti L, Sottini A, **Quiròs-Roldan E**, Puoti M, Castelli F, Cadeo GP, Gorla R, Primi D. Detection of clonal T cell populations with closely related T cell receptor junctional sequences in persons at high risk for human immunodeficiency virus (HIV) infection and in patients acutely infected with HIV. J Infect Dis. 1997 Feb;175(2):272-82. PubMed PMID: 9203647.

217: Bettinardi A, Brugnoli D, **Quiròs-Roldan E**, Malagoli A, La Grutta S, Correr A, Notarangelo LD. Missense mutations in the Fas gene resulting in autoimmune

lymphoproliferative syndrome: a molecular and immunological analysis. Blood. 1997 Feb 1;89(3):902-9. PubMed PMID: 9028321.

218: **Quiròs-Roldan E**, Sottini A, Gulletta M, Stellini R, Puoti M, Primi D, Imberti L. The T-cell receptor repertoires expressed by CD4+ and CD4- large granular lymphocytes derived from the same patients suggest the persistent action of an immune-mediated selection process. Blood. 1996 Sep 15;88(6):2133-43. PubMed PMID: 8822933.

219: Sottini A, **Quiròs-Roldan E**, Albertini A, Primi D, Imberti L. Assessment of T-cell receptor beta-chain diversity by heteroduplex analysis. Hum Immunol. 1996 Jun-Jul;48(1-2):12-22. PubMed PMID: 8824569.

220: Sottini A, Bettinardi A, **Quiròs-Roldan E**, Plebani A, Airò P, Primi D, Imberti L. Evidence for antigenic selection of large granular lymphocytes in a patient with Wiskott-Aldrich syndrome. Blood. 1995 Sep 15;86(6):2240-7. PubMed PMID: 7545024.

221: Sottini A, **Quiròs-Roldan E**, Notarangelo LD, Malagoli A, Primi D, Imberti L. Engrafted maternal T cells in a severe combined immunodeficiency patient express T-cell receptor variable beta segments characterized by a restricted V-D-J junctional diversity. Blood. 1995 Apr 15;85(8):2105-13. PubMed PMID: 7718881.

222: Imberti L, Sottini A, **Quiròs Roldan E**, Albertini A, Mattioli S, Prati E, Primi D. Insertion of a short human immunodeficiency virus (HIV)-2 gp36 sequence into an HIV-1 p24 recombinant protein results in a polypeptide with potent and TCRBV-restricted T cell triggering activity. Eur J Immunol. 1995 Jan;25(1):218-25. PubMed PMID: 7843234.

223: **Quiròs Roldan E**, Sottini A, Bettinardi A, Albertini A, Imberti L, Primi D. Different TCRBV genes generate biased patterns of V-D-J diversity in human T cells. Immunogenetics. 1995;41(2-3):91-100. PubMed PMID: 7806301.

224: **Quiròs Roldan E**, Sottini A, Imberti L, Mattioli S, Albertini A, Primi D.

Superantigen-reactive human T cells express a biased repertoire of T-cell receptor V beta joining regions. Res Immunol. 1994 Sep;145(7):517-31. PubMed PMID: 7754198.

225: Lapadula G, Chatenoud L, Gori A, Castelli F, Di Giambenedetto S, Fabbiani M, Maggiolo F, Focà E, Ladisa N, Sighinolfi L, Di Pietro M, Pan A, Torti C; Italian MASTER Cohort (**including Quiros-Roldan E**) . Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART. PLoS One. 2015 May 28;10(5):e0124741. doi: 10.1371/journal.pone.0124741. eCollection 2015. PubMed PMID: 26020949; PubMed Central PMCID: PMC4447446.

226: **Quiros E**, Piédrola G, Maroto MC. HGV RNA sequences in liver and PBMC. Scand J Clin Lab Invest. 2001 Apr;61(2):119-21. PubMed PMID: 11347978.

227: **Quiros E**, Maroto MC. [Hepatitis B virus. Molecular bases of resistance to new drugs]. Med Clin (Barc). 2000 Sep 16;115(8):297-8. Spanish. PubMed PMID: 11093884.

228: **Quiros E**, Torti C, Carosi G. [Human immunodeficiency virus and antiretroviral therapy resistance]. Enferm Infecc Microbiol Clin. 2000 May;18(5):234-7. Review. Spanish. PubMed PMID: 10974768.

229: **Quiros E**, Bettinardi A, Quirós A, Piédrola G, Maroto MC. Detection of mycobacterial DNA in papulonecrotic tuberculid lesions by polymerase chain reaction. J Clin Lab Anal. 2000;14(4):133-5. PubMed PMID: 10906765.

230: **Quiros E**, Piédrola G, Maroto C. GB virus C in patients with liver disease of unknown etiology. J Clin Lab Anal. 2000;14(2):70-2. PubMed PMID: 10683617.

231: **Quiros E**, Maroto MC. RNA virus of hepatitis G (GB virus) prevalence in health care personnel. Am J Infect Control. 1999 Apr;27(2):176-7. PubMed PMID: 10196494.

232: **Quiros E**, Piédrola G, Maroto C. GBV-RNA detection by polymerase chain

reaction with several primer pairs. Microbios. 1998;95(381):125-30. PubMed PMID: 9872001.

233: **Quirós E**, Piédrola G, Maroto MC. GBV-C RNA presence in several high-risk groups of Spain. Eur J Epidemiol. 1998 Sep;14(6):617-9. PubMed PMID: 9794130.

234: **Quirós E**, Maroto C. [Hepatitis G virus, agent responsible fo hepatitis or is it an innocuous virus?]. Med Clin (Barc). 1998 Jan 24;110(2):62-3. Spanish. PubMed PMID: 9534131.

235: **Quirós E**, Piedrola G, Maroto MC. Detection of enteroviral RNA by a new single-step PCR. Scand J Clin Lab Invest. 1997 Aug;57(5):415-9. PubMed PMID: 9279967.

236: **Quirós E**, Maroto MC, Bettinardi A, González I, Piédrola G. Diagnosis of cutaneous tuberculosis in biopsy specimens by PCR and southern blotting. J Clin Pathol. 1996 Nov;49(11):889-91. PubMed PMID: 8944606; PubMed Central PMCID: PMC500826.

237: **Quirós E**, Maroto MC. [Superantigens: concept and applications in the pathogenesis and treatment of infectious and autoimmune diseases]. An Med Interna. 1996 Jul;13(7):347-52. Review. Spanish. PubMed PMID: 8962982.

238: **Quirós E**, González I, Bettinardi A, Quirós A, Piédrola G, Maroto C. [Demonstration of articular tuberculosis by the polymerase chain reaction and hybridization on synovial membrane samples]. Enferm Infecc Microbiol Clin. 1995 Dec;13(10):633. Spanish. PubMed PMID: 8808481.

239: **Quirós E**, López-Cañabare MJ, Quirós A, Piédrola G, Maroto MC. [Activation of cell death in lymphocytes from individuals infected with HIV]. Enferm Infecc Microbiol Clin. 1995 Nov;13(9):522-6. Spanish. PubMed PMID: 8519834.

240: Primi D, Sottini A, Bettinardi A, **Quiros E**, Albertini A, Imberti L. Evidence for preferential recombination events in normal human T-cell repertoires. Ann N Y

Acad Sci. 1995 Jul 7;756:87-9. PubMed PMID: 7645879.

241: Imberti L, Sottini A, **Quiros E**, Mattioli S, Prati E, Albertini A, Primi D. Construction of a superantigen through a structural modification of an inactive protein. Ann N Y Acad Sci. 1995 Jul 7;756:117-9. PubMed PMID: 7645815.

242: **Quiros E**, García F, Maroto MC, Bernal MC, Cabezas T, Piedrola G. Human immunodeficiency virus type-1 can be detected in monocytes by polymerase chain reaction. J Med Microbiol. 1995 Jun;42(6):411-4. PubMed PMID: 7791205.

243: **Quiros E**, González I. [Immunologic dysfunction and HIV]. Med Clin (Barc). 1995 Feb 11;104(5):178-9. Spanish. PubMed PMID: 7877377.

244: Quirós A, **Quiros E**, González I, Bernal MC, Piedrola G, Maroto MC. Helicobacter pylori seroepidemiology in risk groups. Eur J Epidemiol. 1994 Jun;10(3):299-301. PubMed PMID: 7859841.

245: Cabezas T, **Quiros E**, Garcia F, Hernández-Quero J, Bernal MC, Martinez MA, de la Higuera J, Piédrola G, Maroto MC. Immune complex p24 antigen: a new prognostic marker in human immunodeficiency virus infection. Infection. 1994 Jan-Feb;22(1):4-7. PubMed PMID: 7910149.

246: García F, **Quiros E**, Bernal MC, De Luis B, Leyva A, Piedrola G, Maroto MC. Serum hepatitis B virus DNA detection with S- and C-region-directed probes. J Med Microbiol. 1993 Dec;39(6):473-5. PubMed PMID: 8246268.

247: Quirós A, **Quiros E**, García F, Bernal MC, Hernández-Quero J, Maroto MC. [Helicobacter pylori and HIV infection]. Enferm Infecc Microbiol Clin. 1993 Aug-Sep;11(7):395. Spanish. PubMed PMID: 8399480.

248: **Quiros E**, García F, González I, Cabezas T, Bernal MC, Maroto MC. Diagnosis of HIV-1 infection by PCR with two primer pairs. Eur J Epidemiol. 1993 Jul;9(4):426-9. PubMed PMID: 8243598.

- 249: **Quirós E**, González I. [New techniques for nucleic acid amplification]. Med Clin (Barc). 1993 Jun 19;101(4):141-3. Spanish. PubMed PMID: 8355544.
- 250: **Quirós E**, García F, Cabezas T, González I, Bernal MC, Maroto MC, Piedrola G. [Evaluation of DNA-HIV detection in various population groups]. Enferm Infecc Microbiol Clin. 1993 May;11(5):241-3. Spanish. PubMed PMID: 8324019.
- 251: Maroto MC, Piédrola D, **Quirós E**, García F, Bernal MC. [Annual cost of microbial immunological tests for HIV-positive individuals in a hospital center]. Enferm Infecc Microbiol Clin. 1992 Oct;10(8):462-5. Spanish. PubMed PMID: 1336978.
- 252: García FG, **Quiros E**, Bernal MC, Salmeron J, Maroto MC. An enzyme-linked (alkaline phosphatase) oligonucleotide probe for the detection of serum hepatitis B virus DNA. Liver. 1992 Aug;12(4 Pt 1):179-82. PubMed PMID: 1406081.
- 253: **Quirós E**, García F. [Direct methods for the detection of the human immunodeficiency virus]. Med Clin (Barc). 1992 Jun 20;99(4):147-52. Review. Spanish. PubMed PMID: 1635411.
- 254: García F, **Quirós E**, Bernal MC, Alados JC, González MI, Maroto MC. [Quantification of the levels of p24 antigen and antibodies in human immunodeficiency virus infection]. Enferm Infecc Microbiol Clin. 1992 Feb;10(2):75-8. Spanish. PubMed PMID: 1643142.
- 255: García F, **Quirós E**, Bernal M, Maroto MC. [Absence of HIV infection among the mentally retarded]. Enferm Infecc Microbiol Clin. 1991 Oct;9(8):516. Spanish. PubMed PMID: 1805962.